var title_f10_1_10256="Delivery of PDT";
var content_f10_1_10256=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F57883&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F57883&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Photodynamic therapy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 306px; height: 311px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The same patient photographed during the delivery of photodynamic therapy. The field appears diffusely red to orange, and the tip of the cylindrical diffuser is embedded in the tumor.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Armin Ernst, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_1_10256=[""].join("\n");
var outline_f10_1_10256=null;
var title_f10_1_10257="Tillaux anatomy";
var content_f10_1_10257=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F76624&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F76624&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tillaux fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 354px; height: 549px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Juvenile Tillaux fracture. Mechanism of injury, the anteroinferior tibiofibular ligament avulses a fragment of the medial epiphysis corresponding to the portion of the physis that is still open (top, anterior view; bottom, inferior view).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn with permission from: Cummings, RJ. Distal tibial and fibular fractures. In: Rockwood and Wilkins' Fractures in Children, 6th ed, Beaty, JH, Kasser, JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_1_10257=[""].join("\n");
var outline_f10_1_10257=null;
var title_f10_1_10258="Chronic mucocutaneous candidiasis";
var content_f10_1_10258=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F64895&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F64895&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 604px\">",
"   <div class=\"ttl\">",
"    Chronic mucocutaneous candidiasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 584px; height: 197px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Heaped-up granulomatous lesions of the scalp of a 12-year-old girl with chronic mucocutaneous candidiasis. The same patient also had lesions on the nose and eyelid.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol Kauffman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_1_10258=[""].join("\n");
var outline_f10_1_10258=null;
var title_f10_1_10259="Interactive diabetes case 10: A 45-year old woman with variable glucose values and hypoglycemia unawareness on insulin therapy";
var content_f10_1_10259=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Interactive diabetes case 10: A 45-year old woman with variable glucose values and hypoglycemia unawareness on insulin therapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/1/10259/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/1/10259/contributors\">",
"     Lloyd Axelrod, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/1/10259/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/1/10259/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/1/10259/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/1/10259/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/1/10259/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     CASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;You are asked to see a 45-year old woman because of labile glucose control and recurrent hypoglycemia. At age 28 the patient had gestational diabetes treated with insulin. The baby weighed 8 lbs 6 oz at the time of delivery. Postpartum, the diabetes disappeared completely, only to return one year later. The patient was then treated with oral agents for a few months and then with insulin, which she has taken ever since. Her blood glucose values have always been variable. She had typical symptoms of hypoglycemia including tremulousness, palpitations, and diaphoresis until approximately five years ago. Now, she only rarely has any symptoms of hypoglycemia even when her blood glucose values are between 30 and 50",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.7 and 2.8",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    Sometimes family or coworkers notice inappropriate behavior and have her drink juice. She may have as much as two 8-ounce glasses of orange juice at a time, after which the blood glucose values rise to the 200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (11.1",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    range. She tests her fingerstick blood glucose level four or five times a day. The glucose values in her diary for the last three months are as follows: before breakfast 50 to 250, with most values below 100; two hours after breakfast 48 to 349, with a few values below 100; before lunch, 32 to 303, with many values below 100; before supper, 53 to 285 with about 20 percent of the values below 100; two hours after supper, 136 to 232 with only five tests recorded; and at bedtime, 43 to 182 with only seven tests recorded. The patient has three meals a day, avoids sweets and tries to keep her carbohydrate intake steady at each mealtime, but does not count carbohydrates. Her A1C values have been just above 6 percent. She takes NPH insulin 26 units before breakfast and 18 units at bedtime and uses lispro insulin before breakfast and supper (",
"    <a class=\"graphic graphic_table graphicRef82651 \" href=\"UTD.htm?1/60/1995\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    She estimates that she uses 20 to 30 units of lispro insulin each day. She is on l-thyroxine 150 micrograms a day for hypothyroidism with the TSH level within normal limits and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/58/937?source=see_link\">",
"     lisinopril",
"    </a>",
"    20 mg a day for hypertension. Her father died at age 49 of a heart attack with diabetes diagnosed when he was in military service. Her mother had a goiter removed surgically. Her fraternal twin sister had diabetes with obesity; the diabetes disappeared after bariatric surgery. Her brother is living and well. The patient's weight is 164.5 pounds, height 5' 6\", body mass index 26.5.",
"   </p>",
"   <p>",
"    What is your assessment and plan?",
"   </p>",
"   <p>",
"    A1- You conclude that the patient has type 2 diabetes based on the history of gestational diabetes and the family history; that she has frequent hypoglycemia due to the use of the sliding scale; and that she needs basal insulin (NPH) only once a day. You order anti-thyroid peroxidase antibodies and anti-islet (GAD and IA-2) antibodies. You refer the patient to a nutritionist to learn to count carbohydrates and limit orange juice to 4 ounces at any one time if possible, but never more than 8 ounces, and advise a bedtime snack. You stop the sliding scale coverage. You stop the morning dose of NPH insulin and change the bedtime dose of NPH insulin to 35 units (about 80 percent of the current total NPH dose per 24 hours). (See",
"    <a class=\"medical medical_answer\" href=\"UTD.htm?10/1/10259-a1?source=see_link\">",
"     \"Interactive diabetes case 10: A 45-year old woman with variable glucose values and hypoglycemia unawareness on insulin therapy - A1\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A2- You conclude that the patient has type 1 diabetes based on the labile blood glucose values, the absence of obesity, the presence of hypothyroidism and the family history of thyroid disease; that she has frequent hypoglycemia owing to excessive doses of basal insulin at bedtime, and that she needs less basal insulin at that time. You order anti-thyroid peroxidase antibodies and anti-islet (GAD and IA-2) antibodies. You refer the patient to a nutritionist to learn to count carbohydrates and limit orange juice to 4 ounces at any one time if possible, but never more than 8 ounces, and advise a bedtime snack. You reduce the bedtime dose of NPH insulin to 14 units. (See",
"    <a class=\"medical medical_answer\" href=\"UTD.htm?10/1/10259-a2?source=see_link\">",
"     \"Interactive diabetes case 10: A 45-year old woman with variable glucose values and hypoglycemia unawareness on insulin therapy - A2\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A3- You cannot decide whether the patient has type 1 or type 2 diabetes. You conclude that she has labile glucose levels due to excessive doses of basal insulin at bedtime and excessive doses of lispro by sliding scale, and over-treatment of hypoglycemia. You order anti-thyroid peroxidase antibodies and anti-islet (GAD and IA-2) antibodies. You refer the patient to a nutritionist to learn to count carbohydrates and limit orange juice to 4 ounces at any one time if possible, but never more than 8 ounces, and advise a bedtime snack. You reduce the bedtime dose of NPH insulin to 10 units. You change the sliding scale (",
"    <a class=\"graphic graphic_table graphicRef61622 \" href=\"UTD.htm?5/49/5915\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_answer\" href=\"UTD.htm?10/1/10259-a3?source=see_link\">",
"     \"Interactive diabetes case 10: A 45-year old woman with variable glucose values and hypoglycemia unawareness on insulin therapy - A3\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/43/692?source=see_link\">",
"       \"Patient information: Type 1 diabetes (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/44/33475?source=see_link\">",
"       \"Patient information: Type 2 diabetes (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?14/12/14531?source=see_link\">",
"       \"Patient information: Low blood sugar in people with diabetes (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/26/36259?source=see_link\">",
"       \"Patient information: Diabetes mellitus type 1: Overview (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/22/9572?source=see_link\">",
"       \"Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/43/39603?source=see_link\">",
"       \"Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?3/63/4083?source=see_link\">",
"       \"Patient information: Hypoglycemia (low blood sugar) in diabetes mellitus (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4146 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-60.18.131.125-4DC6258CCE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_1_10259=[""].join("\n");
var outline_f10_1_10259=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      CASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/4146\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/4146|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/60/1995\" title=\"table 1\">",
"      Sliding scale 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/49/5915\" title=\"table 2\">",
"      Sliding scale 2",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_answer\" href=\"UTD.htm?10/1/10259-a1?source=related_link\">",
"      Interactive diabetes case 10: A 45-year old woman with variable glucose values and hypoglycemia unawareness on insulin therapy - A1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_answer\" href=\"UTD.htm?10/1/10259-a2?source=related_link\">",
"      Interactive diabetes case 10: A 45-year old woman with variable glucose values and hypoglycemia unawareness on insulin therapy - A2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_answer\" href=\"UTD.htm?10/1/10259-a3?source=related_link\">",
"      Interactive diabetes case 10: A 45-year old woman with variable glucose values and hypoglycemia unawareness on insulin therapy - A3",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/26/36259?source=related_link\">",
"      Patient information: Diabetes mellitus type 1: Overview (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/22/9572?source=related_link\">",
"      Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/63/4083?source=related_link\">",
"      Patient information: Hypoglycemia (low blood sugar) in diabetes mellitus (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/12/14531?source=related_link\">",
"      Patient information: Low blood sugar in people with diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/43/39603?source=related_link\">",
"      Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/43/692?source=related_link\">",
"      Patient information: Type 1 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/44/33475?source=related_link\">",
"      Patient information: Type 2 diabetes (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_1_10260="Anatomy of the radial artery";
var content_f10_1_10260=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F55221&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F55221&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 484px\">",
"   <div class=\"ttl\">",
"    Anatomy of the radial artery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 464px; height: 631px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the arterial supply to the ventral surface of the hand. Collateral circulation to the radial artery is provided by the ulnar artery through the deep and superficial volar arterial arches.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     <p>",
"      &nbsp;",
"     </p>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_1_10260=[""].join("\n");
var outline_f10_1_10260=null;
var title_f10_1_10261="Albendazole: Pediatric drug information";
var content_f10_1_10261=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Albendazole: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"    see \"Albendazole: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?30/36/31300?source=see_link\">",
"    see \"Albendazole: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F130833\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Albenza&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1044931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anthelmintic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1044925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"      see \"Albendazole: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children and Adults: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neurocysticercosis",
"     <i>",
"      (Taenia solium)",
"     </i>",
"     :",
"     <b>",
"      Note:",
"     </b>",
"     Patients should receive concurrent corticosteroid for the first week of albendazole therapy and anticonvulsant therapy as required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &lt;60 kg: 15 mg/kg/day in 2 divided doses (maximum: 800 mg/day) for 8-30 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &ge;60 kg: 400 mg twice daily for 8-30 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hydatid disease",
"     <i>",
"      (Echinococcus granulosus)",
"     </i>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &lt;60 kg: 15 mg/kg/day in 2 divided doses (maximum: 800 mg/day); 28-day cycle followed by a 14-day albendazole-free interval, for a total of 3 cycles",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &ge;60 kg: 400 mg twice daily; 28-day cycle followed by a 14-day albendazole-free interval, for a total of 3 cycles",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Ancylostoma caninum",
"     </i>",
"     , ascariasis (roundworm), hookworm, trichuriasis (whipworm): 400 mg as a single dose (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Ascariasis",
"     </i>",
"     : Children 12 months to 2 years: 200 mg as a single dose (World Health Organization Model Formulary for Children, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Baylisascaris procyonis",
"     </i>",
"     : Children: 25 mg/kg/day for 20 days started as soon as possible (up to 3 days after possible infection) may  prevent clinical disease and is recommended for children with known exposure (eg, ingestion of raccoon stool or contaminated soil). No drug has been demonstrated to be effective (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capillariasis: 400 mg once daily for 10 days (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Clonorchis sinensis",
"     </i>",
"     (Chinese liver fluke): 10 mg/kg/day once daily for 7 days (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cutaneous larva migrans: 400 mg once daily for 3 days (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Enterobius vermicularis",
"     </i>",
"     (pinworm): 400 mg as a single dose; repeat in 2 weeks (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Filariasis (",
"     <i>",
"      Mansonella perstans",
"     </i>",
"     ): 400 mg twice daily for 10 days (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Filariasis (",
"     <i>",
"      Wuchereria Bancroft",
"     </i>",
"     , microfilaria reduction or suppression): 400 mg as a single dose (in combination with either ivermectin or diethylcarbamazine).",
"     <b>",
"      Note:",
"     </b>",
"     Albendazole/ivermectin combination does not kill all the adult worms (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Giardiasis",
"     <i>",
"      (Giardia duodenalis)",
"     </i>",
"     (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2009):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 10 mg/kg/day once daily for 5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults:  400 mg once daily for 5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Gnathostoma spinigerum",
"     </i>",
"     (Gnathostomiasis): 400 mg twice daily for 21 days (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Gongylonema",
"     </i>",
"     sp (Gongylonemiasis): 400 mg once daily for 3 days (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Microsporidia",
"     </i>",
"     infection (except",
"     <i>",
"      Enterocytozoon sp.",
"     </i>",
"     and",
"     <i>",
"      V. corneae",
"     </i>",
"     ) in HIV-exposed/positive infants and children: 15 mg/kg/day in 2 divided doses (maximum: 800 mg/day) continued until immune reconstitution after HAART initiation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Microsporidiosis in non-HIV patients (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2009):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Disseminated: 400 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intestinal: 400 mg twice daily for 21 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: 400 mg twice daily in combination with fumagillin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Strongyloidiasis (",
"     <i>",
"      Strongyloides stercoralis",
"     </i>",
"     ): 400 mg twice daily for 7 days (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Trichinellosis (",
"     <i>",
"      Trichinella spiralis",
"     </i>",
"     ): 400 mg twice daily for 8-14 days (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Visceral larva migrans (",
"     <i>",
"      Toxocariasis",
"     </i>",
"     ): 400 mg twice daily for 5 days (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2009)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F130812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Albenza&reg;: 200 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F130799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1044934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer with food. For children who have difficulty swallowing whole tablets, tablet may be crushed or chewed and swallowed with a drink of water.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1044928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store between 20&deg;C and 25&deg;C (68&deg;F to 77&deg;F)",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1044933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of",
"     <i>",
"      Taenia solium",
"     </i>",
"     (pork tapeworm) and treatment of cystic hydatid disease of the liver, lung, and peritoneum caused by the larval form of",
"     <i>",
"      Echinococcus granulosus",
"     </i>",
"     (dog tapeworm) [FDA approved in pediatric patients (age not specified) and adults]. Is also active against and has been used in the treatment of",
"     <i>",
"      Ascaris lumbricoides",
"     </i>",
"     (roundworm),",
"     <i>",
"      Ancylostoma caninum",
"     </i>",
"     ,",
"     <i>",
"      Ancylostoma duodenale",
"     </i>",
"     ,",
"     <i>",
"      Necator americanus",
"     </i>",
"     (hookworm),",
"     <i>",
"      Enterobius vermicularis",
"     </i>",
"     (pinworm), cutaneous larva migrans,",
"     <i>",
"      Gnathostoma spinigerum",
"     </i>",
"     ,",
"     <i>",
"      Gongylonema",
"     </i>",
"     sp:",
"     <i>",
"      Mansonella perstans",
"     </i>",
"     (filariasis),",
"     <i>",
"      Opisthorchis sinensis",
"     </i>",
"     (liver fluke), visceral larva migrans (toxocariasis),",
"     <i>",
"      Echinococcus multilocularis",
"     </i>",
"     ,",
"     <i>",
"      Clonorchis sinensis",
"     </i>",
"     (Chinese liver fluke),",
"     <i>",
"      Giardia lamblia",
"     </i>",
"     ,",
"     <i>",
"      Cysticecus cellulosae",
"     </i>",
"     ,",
"     <i>",
"      Trichuris trichiura",
"     </i>",
"     (whipworm), microsporidiosis,",
"     <i>",
"      Capillaria philippinensis",
"     </i>",
"     ,",
"     <i>",
"      Baylisascaris procyonis",
"     </i>",
"     , and",
"     <i>",
"      Strongyloides stercoralis",
"     </i>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3195081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Albenza&reg; may be confused with Aplenzin&trade;, Relenza&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Albenza [U.S.] may be confused with Avanza brand name for mirtazapine [Australia]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F130871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, fever, headache, intracranial pressure increased, meningeal signs, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: LFTs increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Acute liver failure, acute renal failure, aplastic anemia, agranulocytosis, erythema multiforme, granulocytopenia, hepatitis, hypersensitivity reaction, leukopenia, neutropenia, pancytopenia, rash, Stevens-Johnson syndrome, thrombocytopenia, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1044937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to albendazole, any component, or the benzimidazole class of compounds",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1044924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with abnormal liver function tests or decreased total leukocyte count (increased risk for hepatotoxicity and bone marrow suppression); discontinue albendazole if significant elevation of liver enzymes occur; may restart therapy when liver enzymes decrease to pretreatment values. During treatment, death of parasites within the brain may produce neurological symptoms (eg, seizures, increased ICP, focal signs) and an inflammatory response; corticosteroids should be used during the first week of treatment to prevent cerebral hypertensive episodes. In patients treated with albendazole for other conditions, pre-existing neurocysticercosis may be uncovered and neurological symptoms (eg, seizures, increased ICP, and focal signs) may occur soon after treatment; appropriate steroid and anticonvulsant therapy should be started immediately. Albendazole may induce further retinal damage in patients having retinal lesions with neurocysticercosis.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1044923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Agranulocytosis, aplastic anemia, granulocytopenia, leukopenia, and pancytopenia have occurred leading to fatalities (rare). Patients with liver disease, including hepatic echinococcosis, appear to be at greater risk for bone marrow suppression. Monitor blood counts at the beginning of each 28-day cycle and every 2 weeks while on therapy. Discontinue therapy in all patients who develop clinically significant decreases in blood cell counts. Women of childbearing age should only begin treatment after a negative pregnancy test and should be cautioned against becoming pregnant during and for at least 1 month after treatment cessation with albendazole since it may cause fetal harm.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F130860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F130807\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoquinolines (Antimalarial): May decrease the serum concentration of Anthelmintics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase serum concentrations of the active metabolite(s) of Albendazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1044939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bioavailability is increased (up to 5 times) when taken with a fatty meal",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F130808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F130820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Albendazole has been shown to be teratogenic in laboratory animals and should not be used during pregnancy, if at all possible. Women should be advised to avoid pregnancy for at least 1 month following therapy. Discontinue if pregnancy occurs during treatment.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1044930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor liver function tests, CBC at start of each cycle and every 2 weeks during therapy, fecal specimens for ova and parasites; pregnancy test",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1044922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds to &beta;-tubulin in parasite cells inhibiting tubulin polymerization which results in the loss of cytoplasmic microtubules and inhibition of glucose uptake",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1044936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     In pediatric patients (6-13 years), pharmacokinetic values were reported to be similar to adult data.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Poorly absorbed from the GI tract",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Widely distributed throughout the body including urine, bile, liver, cyst wall, cyst fluid, and CSF",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 70%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensive first-pass metabolism; hepatic metabolism to albendazole sulfoxide, an active metabolite",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Albendazole sulfoxide: 8-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: 2-5 hours for the metabolite",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Biliary",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F6074932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?30/36/31300?source=see_link\">",
"      see \"Albendazole: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Follow physician's suggestions to prevent reinfection. Notify physician if fever, abdominal pain, vomiting, yellowing of skin or eyes, darkening of urine, or light colored stools occur. Women of childbearing age should be advised to avoid becoming pregnant while on albendazole or within 1 month after discontinuing treatment. May cause dizziness and impair ability to perform activities requiring mental alertness.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Baranwal AK, Singhi PD, Khandelwal N, et al, &ldquo;Albendazole Therapy in Children With Focal Seizures and Single Small Enhancing Computerized Tomographic Lesions: A Randomized, Placebo-Controlled, Double Blind Trial,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1998, 17(8):696-700.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/1/10261/abstract-text/9726343/pubmed\" id=\"9726343\" target=\"_blank\">",
"        9726343",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf%20\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/1/10261/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jung H, Sanchez M, Gonzalez-Astiazaran A, et al, &ldquo;Clinical Pharmacokinetics of Albendazole in Children With Neurocysticercosis,&rdquo;",
"      <i>",
"       Am J Ther",
"      </i>",
"      , 1997, 4(1):23-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/1/10261/abstract-text/10423586/pubmed\" id=\"10423586\" target=\"_blank\">",
"        10423586",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Paul I, Gnanamani G, and Nallam NR, &ldquo;Intestinal Helminth Infections Among School Children in Visakhapatnam,&rdquo;",
"      <i>",
"       Indian J Pediatr",
"      </i>",
"      , 1999, 66(5):669-73.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pengsaa K, Sirivichayakul C, Pojjaroen-anant C, et al, &ldquo;Albendazole Treatment for",
"      <i>",
"       Giardia intestinalis",
"      </i>",
"      Infections in School Children,&rdquo;",
"      <i>",
"       Southeast Asian J Trop Med Public Health",
"      </i>",
"      , 1999, 30(1):78-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/1/10261/abstract-text/10695793/pubmed\" id=\"10695793\" target=\"_blank\">",
"        10695793",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Red Book: 2009 Report of the Committee on Infectious Diseases",
"      </i>",
"      , 28th ed, Pickering LK, ed, Elk Grove Village, IL: American Academy of Pediatrics, 2009.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      World Health Organization, \"WHO Model Formulary for Children,\" 2010.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13269 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-6CC31590FA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_1_10261=[""].join("\n");
var outline_f10_1_10261=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130833\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1044931\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1044925\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130812\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130799\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1044934\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1044928\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1044933\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3195081\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130871\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1044937\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1044924\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1044923\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130860\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130807\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1044939\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130808\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130820\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1044930\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1044922\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1044936\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6074932\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13269\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13269|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=related_link\">",
"      Albendazole: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?30/36/31300?source=related_link\">",
"      Albendazole: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_1_10262="Female pelvic bones sagittal";
var content_f10_1_10262=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F87092&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F87092&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 616px\">",
"   <div class=\"ttl\">",
"    Sagittal view of the female pelvic bones",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 596px; height: 508px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission: Cleveland Clinic Center for Medical Art &amp; Photography &copy; 2004-2012. All Rights Reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_1_10262=[""].join("\n");
var outline_f10_1_10262=null;
var title_f10_1_10263="Epidemiology of Staphylococcus aureus bacteremia in adults";
var content_f10_1_10263=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology of Staphylococcus aureus bacteremia in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/1/10263/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/1/10263/contributors\">",
"     Vance G Fowler, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/1/10263/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/1/10263/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/1/10263/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/1/10263/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/1/10263/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/1/10263/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Staphylococcus aureus is a leading cause of both community-acquired and healthcare-associated bacteremia. Several important underlying conditions predispose patients to the development of S. aureus bacteremia (SAB). The morbidity and mortality of SAB is high even when appropriate therapy is given.",
"   </p>",
"   <p>",
"    The presence of individual risk factors substantially affects clinical management. Thus, clinicians need to specifically inquire as to the presence or absence of these risk factors before making clinical decisions regarding treatment.",
"   </p>",
"   <p>",
"    The epidemiology of and risk factors for SAB in adults will be reviewed here. The treatment of SAB is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24249?source=see_link\">",
"     \"Treatment of Staphylococcus aureus bacteremia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacteremia due to S. aureus can be classified into three categories: healthcare-associated hospital onset (nosocomial), community-acquired, and healthcare-associated community onset (non-nosocomial) (eg, long-term care facilities) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10263/abstract/1\">",
"     1",
"    </a>",
"    ]. In a prospective cohort study of 504 bloodstream infections (BSIs) seen at an academic center and two community hospitals in North Carolina between late 2000 and early 2001, 35 percent were nosocomial, 28 percent were community-acquired, and 37 percent were healthcare-associated community-onset [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10263/abstract/1\">",
"     1",
"    </a>",
"    ]. Methicillin-resistant S. aureus accounted for most nosocomial and healthcare-associated community-onset infections (61 and 52 percent, respectively), but only a small proportion of community-acquired infections (14 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of SAB for each of the above categories has increased significantly over the last several decades. The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      From 1980 to 1989, the National Nosocomial Infections Surveillance System (NNIS) of the Centers for Disease Control and Prevention (CDC) reported increases in the rates of SAB ranging from 122 to 283 percent in individual hospitals [",
"      <a class=\"abstract\" href=\"UTD.htm?10/1/10263/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The rate of nosocomial SAB at Emory University Hospital increased from 0.75 to 2.80 cases per 1000 discharges from 1980 to 1993, while the rate of community-acquired SAB simultaneously increased from 0.84 to 2.43 cases per 1000 discharges [",
"      <a class=\"abstract\" href=\"UTD.htm?10/1/10263/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In Denmark, the annual incidence of SAB increased from 2.7 cases per 100,000 in 1960 to 19.2 cases per 100,000 in 1990; increases in the rate of nosocomial SAB accounted for most of this change [",
"      <a class=\"abstract\" href=\"UTD.htm?10/1/10263/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a more contemporary study from Finland, there was a 55 percent increase in the incidence of SAB between 1995 and 2001 (from 11 to 17 per 100,000), which was most pronounced in the elderly [",
"      <a class=\"abstract\" href=\"UTD.htm?10/1/10263/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Nosocomial",
"    </span>",
"    &nbsp;&mdash;&nbsp;SAB has become a leading cause of nosocomial bloodstream infections (BSIs) in the United States. This was illustrated in a prospective analysis of over 24,000 nosocomial BSIs occurring in 49 hospitals in the United States between 1995 to 2002, S. aureus was the second most common cause after coagulase-negative staphylococci, accounting for 20 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10263/abstract/6\">",
"     6",
"    </a>",
"    ]. The proportion of S. aureus isolates that were due to methicillin-resistant increased from 22 percent in 1995 to 57 percent in 2001.",
"   </p>",
"   <p>",
"    This trend is due largely to the increasing use of intravascular catheters and subsequent catheter-associated staphylococcal bacteremia. In a prospective case-control study of hospitalized Danish patients, the presence of a central venous catheter was the single greatest risk factor for the development of SAB [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10263/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37464?source=see_link&amp;anchor=H8#H8\">",
"     \"Epidemiology, pathogenesis, and microbiology of intravascular catheter infections\", section on 'Microbiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with hospital-acquired SAB tend to be older, frequently have one or more comorbid illnesses, and typically have one or more of the following risk factors:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Intravascular catheter",
"     </li>",
"     <li>",
"      Respiratory illness",
"     </li>",
"     <li>",
"      Surgical wound",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As an example, bacteremia occurred in 56 of 119 cases (47 percent) of serious S. aureus infections seen by infectious diseases consultants at a tertiary care center over a 33 month period [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10263/abstract/8\">",
"     8",
"    </a>",
"    ]. Ninety-one percent of bacteremic patients had one or more predisposing medical conditions, such as diabetes mellitus, immunosuppressive drugs, or malignancy. Most bacteremic patients also had some breach in normal host protective barriers (wounds, needle use, intravascular devices).",
"   </p>",
"   <p>",
"    The seriousness of healthcare-associated hospital onset SAB is demonstrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 20 percent of patients develop metastatic complications, including infective endocarditis (IE) in 6 to 7 percent of cases. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/31/14840?source=see_link&amp;anchor=H9#H9\">",
"       \"Epidemiology, risk factors and microbiology of infective endocarditis\", section on 'Nosocomial and healthcare-associated endocarditis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Approximately 20 to 30 percent die from their bacteremia [",
"      <a class=\"abstract\" href=\"UTD.htm?10/1/10263/abstract/9,10\">",
"       9,10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hospital-acquired S. aureus infections are likely to be methicillin-resistant and are therefore more difficult and costly to treat than those that are methicillin-susceptible [",
"      <a class=\"abstract\" href=\"UTD.htm?10/1/10263/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Community-acquired",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of community-acquired SAB, particularly in the absence of an identifiable focus of infection, is an important marker for complicated staphylococcal infection. Over 40 percent of patients with community-acquired SAB have metastatic infections [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10263/abstract/9\">",
"     9",
"    </a>",
"    ], including IE [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10263/abstract/12,13\">",
"     12,13",
"    </a>",
"    ], and as many as 90 percent develop one or more complications [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10263/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The frequency of IE was evaluated in a prospective multicenter assessment of 505 consecutive patients with SAB [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10263/abstract/12\">",
"     12",
"    </a>",
"    ]. IE was present in 21 percent of those with community-acquired infection, a rate that was almost three times than seen with hospital-acquired SAB [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10263/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mortality rates of patients with community-acquired SAB are similar to those with hospital-acquired infection. Patients with community-acquired SAB are more frequently injection drug users (IDUs) or have a clinically inapparent source of bacteremia (such as vertebral osteomyelitis or epidural abscess).",
"   </p>",
"   <p>",
"    An increasing problem since the 1990s is infection with community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA), which is genetically distinct from traditional strains of hospital-acquired MRSA. Although CA-MRSA typically causes skin and soft tissue infections, it can also cause bacteremia. In an analysis of 132 cases of MRSA BSIs in patients at an urban public hospital in Atlanta in 2004, molecular typing studies demonstrated that 34 percent of isolates were CA-MRSA [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10263/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/53/8026?source=see_link\">",
"     \"Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Healthcare-associated community onset",
"    </span>",
"    &nbsp;&mdash;&nbsp;Healthcare-associated community onset (non-nosocomial) infection is an increasing reported category that is different from nosocomial and community-acquired infections. The following definition has been proposed: infection diagnosed within 48 hours of admission in an outpatient with extensive healthcare contact, as defined by [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10263/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intravenous therapy, wound care, or specialized nursing care at home, or intravenous chemotherapy within the prior 30 days",
"     </li>",
"     <li>",
"      Residence in a nursing home or other long-term care facility",
"     </li>",
"     <li>",
"      Hospitalization in an acute care hospital for two or more days within the prior 90 days",
"     </li>",
"     <li>",
"      Dialysis or receipt of intravenous therapy within the prior 30 days",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The frequency of such infections as a cause of BSI was illustrated in the prospective cohort study cited above of 504 patients with bacteremia who were admitted to an academic center or two community hospitals: 186 (37 percent) were considered to have healthcare-associated community onset BSI [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10263/abstract/1\">",
"     1",
"    </a>",
"    ]. Intravascular catheters are playing an increasing role in these infections [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10263/abstract/1,3,16\">",
"     1,3,16",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Prosthetic device'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    SAB acquired in long-term care facilities (LTCF; eg, nursing homes) typically affects elderly and chronically ill patients. Skin or soft tissue lesions such as decubitus ulcers, diabetic foot ulcers, or wounds are common causes of SAB in individuals who reside in LTCF. Clinical clues suggesting the presence of metastatic infection (eg, back or joint pain) are often absent in elderly patients. As a result, a careful bedside evaluation must be performed in all such individuals with SAB.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Antimicrobial resistance",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Methicillin",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With respect to nosocomial MRSA infection, in general the burden of methicillin-resistant Staphylococcus aureus (MRSA) is increasing. However, the incidence of MRSA catheter associated bloodstream infections in United States intensive care units appears to be decreasing [",
"      <a class=\"abstract\" href=\"UTD.htm?10/1/10263/abstract/17\">",
"       17",
"      </a>",
"      ]. This was illustrated in a review of over 33,500 episodes of central line associated bloodstream infections between 2001 and 2007; declines in MRSA central line associated blood stream infection incidence ranged from 51 to 64 percent. These findings call into question the utility of performing active MRSA surveillance rather than focusing on reducing healthcare acquired infections in general. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/53/8026?source=see_link\">",
"       \"Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17338?source=see_link\">",
"       \"Prevention and control of methicillin-resistant Staphylococcus aureus in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      With respect to community-acquired MRSA infection, health care contact (eg, prior hospitalization) remains an important risk factor [",
"      <a class=\"abstract\" href=\"UTD.htm?10/1/10263/abstract/18\">",
"       18",
"      </a>",
"      ], but there are numerous reports of patients with no identifiable health care contacts or other risk factors [",
"      <a class=\"abstract\" href=\"UTD.htm?10/1/10263/abstract/19-21\">",
"       19-21",
"      </a>",
"      ]. As an example, a retrospective chart review found a marked increase in the number of children without an identifiable risk factor who were hospitalized for community-acquired MRSA infection in the period 1993 to 1995 compared to 1988 to 1990 (259 versus 10 per 100,000 admissions) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/1/10263/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Community-associated MRSA infections primarily cause skin and soft tissue infections [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10263/abstract/22,23\">",
"     22,23",
"    </a>",
"    ], although bacteremia does occur [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10263/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/53/8026?source=see_link&amp;anchor=H4#H4\">",
"     \"Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults\", section on 'Community-associated methicillin-resistant Staphylococcus aureus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With respect to healthcare-associated community onset infection, a retrospective population-based study from four metropolitan areas of Connecticut in 1998 found that 15 percent of cases of community onset SAB were due to MRSA [",
"      <a class=\"abstract\" href=\"UTD.htm?10/1/10263/abstract/16\">",
"       16",
"      </a>",
"      ]. The majority of patients with MRSA bacteremia had had contact with the healthcare system, including 47 percent with an indwelling catheter. Similar findings were noted in a prospective cohort study that included 186 patients with healthcare-associated community onset BSI seen in late 2000 and early 2001: 52 percent were due to MRSA and 42 percent were receiving intravenous or intravascular therapy at home or in a clinic [",
"      <a class=\"abstract\" href=\"UTD.htm?10/1/10263/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Institutionalized patients are often colonized with MRSA. Thus, bacteremia due to MRSA is much more frequent among those with long-term care facility-acquired SAB or other intensive health care contact than in patients with classic community-acquired SAB without known predisposing conditions (52 versus 14 percent in the prospective cohort study) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10263/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Vancomycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Much less common than MRSA are S. aureus isolates with intermediate susceptibility or resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    . Bacteremia has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10263/abstract/24\">",
"     24",
"    </a>",
"    ]. These infections are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/13/15575?source=see_link\">",
"     \"Microbiology of methicillin-resistant Staphylococcus aureus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Prosthetic device",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any implanted foreign body that becomes infected is a potential source for SAB. Implanted devices include vascular, urologic, and orthopedic prostheses and devices.",
"   </p>",
"   <p>",
"    Intravascular catheters are both the most common cause of SAB in hospitalized patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10263/abstract/7\">",
"     7",
"    </a>",
"    ] and an increasingly important cause of community-acquired infection [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10263/abstract/1,3,16\">",
"     1,3,16",
"    </a>",
"    ]. These devices serve as a direct conduit into the intravascular space, allowing easy access for S. aureus to enter the bloodstream. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37464?source=see_link\">",
"     \"Epidemiology, pathogenesis, and microbiology of intravascular catheter infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Injection drug use",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to patients with catheter-associated SAB, injection drug users (IDUs) who develop SAB are usually young and otherwise healthy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10263/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. The combination of high skin colonization rate with S. aureus and repeated parenteral injection of nonsterile material makes IDUs prone to SAB [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10263/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. IDUs also have a high rate of nasal colonization with S. aureus, and the phage type of the colonizing organism typically matches that of the isolate recovered from the blood [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10263/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Nasal colonization'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Underlying conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inherited defects in white blood cell function or immune responses such as Job's syndrome, Chediak-Higashi syndrome, and Wiskott-Aldrich syndrome also predispose patients to recurrent staphylococcal infections [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10263/abstract/32\">",
"     32",
"    </a>",
"    ]. (See appropriate topic reviews).",
"   </p>",
"   <p>",
"    Patients with conditions conferring increased risk for nasal colonization (such as patients with diabetes and patients who are hemodialysis-dependent) are also more prone to S. aureus infection including SAB [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10263/abstract/33-35\">",
"     33-35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Nasal colonization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with S. aureus nasal colonization are at increased risk for SAB [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10263/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. Among 14,000 patients screened for S. aureus nasal carriage on hospital admission, nosocomial SAB was observed more frequently among nasal carriers (1.2 versus 0.4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10263/abstract/36\">",
"     36",
"    </a>",
"    ]. However, nasal carriers had significantly lower rates of SAB-related mortality (8 versus 32 percent)",
"   </p>",
"   <p>",
"    Differences in the immune response between S. aureus carriers and noncarriers may explain the lower mortality among carriers. Among healthy S. aureus carriers, antibody response against the colonizing strain has been observed [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10263/abstract/37\">",
"     37",
"    </a>",
"    ]. This strain-specific immunity may contribute to the improved mortality outcome for nasal carriers compared to noncarriers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190976558\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Staphylococcus aureus is a leading cause of both community-acquired and healthcare-associated bacteremia. The morbidity and mortality of SAB is high even when appropriate therapy is given. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bacteremia due to S. aureus can be classified into three categories: healthcare-associated hospital onset (nosocomial), community-acquired, and healthcare-associated community onset (non-nosocomial) (eg, long-term care facilities). The incidence of SAB for each of the above categories has increased significantly over the last several decades. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      SAB has become a leading cause of nosocomial bloodstream infections in the United States. This trend is due largely to the increasing use of intravascular catheters. Patients with hospital-acquired SAB tend to be older, frequently have one or more comorbid illnesses, and typically have one or more of the following risk factors: an intravascular catheter, a respiratory illness, or a surgical wound. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Nosocomial'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The presence of community-acquired SAB, particularly in the absence of an identifiable focus of infection, is an important marker for complicated staphylococcal infection. An increasing problem since the 1990s is infection with community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA), which is genetically distinct from traditional strains of hospital-acquired MRSA. Although CA-MRSA typically causes skin and soft tissue infections, it can also cause bacteremia. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Community-acquired'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intravascular catheters are playing an increasing role in healthcare-associated community onset (non-nosocomial) SAB. SAB acquired in long-term care facilities (LTCF; eg, nursing homes) typically affects older adult and chronically-ill patients. Skin or soft tissue lesions such as decubitus ulcers, diabetic foot ulcers, or wounds are common causes of SAB in individuals who reside in LTCF. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Healthcare-associated community onset'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In general, the burden of MRSA is increasing. However, the incidence of MRSA catheter associated bloodstream infections in United States intensive care units has been decreasing. Healthcare contact (eg, prior hospitalization) is an important risk factor for MRSA infection, but there are numerous reports of patients with no identifiable healthcare contacts or other risk factors. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Methicillin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Any implanted foreign body that becomes infected is a potential source for SAB. Implanted devices include vascular, urologic, and orthopedic prostheses and devices. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Prosthetic device'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In contrast to patients with catheter-associated SAB, injection drug users (IDUs) who develop SAB are usually young and otherwise healthy. The combination of high skin colonization rate with S. aureus and repeated parenteral injection of nonsterile material makes IDUs prone to SAB. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Injection drug use'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Inherited defects in white blood cell function or immune responses such as Job's syndrome, Chediak-Higashi syndrome, and Wiskott-Aldrich syndrome predispose patients to recurrent staphylococcal infections. Patients with nasal colonization as well as those with conditions conferring increased risk for nasal colonization (eg, diabetes, hemodialysis) are also more prone to S. aureus infection, including SAB. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Underlying conditions'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Nasal colonization'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10263/abstract/1\">",
"      Friedman ND, Kaye KS, Stout JE, et al. Health care--associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 2002; 137:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10263/abstract/2\">",
"      Banerjee SN, Emori TG, Culver DH, et al. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System. Am J Med 1991; 91:86S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10263/abstract/3\">",
"      Steinberg JP, Clark CC, Hackman BO. Nosocomial and community-acquired Staphylococcus aureus bacteremias from 1980 to 1993: impact of intravascular devices and methicillin resistance. Clin Infect Dis 1996; 23:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10263/abstract/4\">",
"      Frimodt-M&oslash;ller N, Espersen F, Skinh&oslash;j P, Rosdahl VT. Epidemiology of Staphylococcus aureus bacteremia in Denmark from 1957 to 1990. Clin Microbiol Infect 1997; 3:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10263/abstract/5\">",
"      Lyytik&auml;inen O, Ruotsalainen E, J&auml;rvinen A, et al. Trends and outcome of nosocomial and community-acquired bloodstream infections due to Staphylococcus aureus in Finland, 1995-2001. Eur J Clin Microbiol Infect Dis 2005; 24:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10263/abstract/6\">",
"      Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10263/abstract/7\">",
"      Jensen AG, Wachmann CH, Poulsen KB, et al. Risk factors for hospital-acquired Staphylococcus aureus bacteremia. Arch Intern Med 1999; 159:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10263/abstract/8\">",
"      Musher DM, Lamm N, Darouiche RO, et al. The current spectrum of Staphylococcus aureus infection in a tertiary care hospital. Medicine (Baltimore) 1994; 73:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10263/abstract/9\">",
"      Lautenschlager S, Herzog C, Zimmerli W. Course and outcome of bacteremia due to Staphylococcus aureus: evaluation of different clinical case definitions. Clin Infect Dis 1993; 16:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10263/abstract/10\">",
"      Raad II, Sabbagh MF. Optimal duration of therapy for catheter-related Staphylococcus aureus bacteremia: a study of 55 cases and review. Clin Infect Dis 1992; 14:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10263/abstract/11\">",
"      Abramson MA, Sexton DJ. Nosocomial methicillin-resistant and methicillin-susceptible Staphylococcus aureus primary bacteremia: at what costs? Infect Control Hosp Epidemiol 1999; 20:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10263/abstract/12\">",
"      Chang FY, MacDonald BB, Peacock JE Jr, et al. A prospective multicenter study of Staphylococcus aureus bacteremia: incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance. Medicine (Baltimore) 2003; 82:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10263/abstract/13\">",
"      Bayer AS, Lam K, Ginzton L, et al. Staphylococcus aureus bacteremia. Clinical, serologic, and echocardiographic findings in patients with and without endocarditis. Arch Intern Med 1987; 147:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10263/abstract/14\">",
"      Willcox PA, Rayner BL, Whitelaw DA. Community-acquired Staphylococcus aureus bacteraemia in patients who do not abuse intravenous drugs. QJM 1998; 91:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10263/abstract/15\">",
"      Seybold U, Kourbatova EV, Johnson JG, et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated blood stream infections. Clin Infect Dis 2006; 42:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10263/abstract/16\">",
"      Morin CA, Hadler JL. Population-based incidence and characteristics of community-onset Staphylococcus aureus infections with bacteremia in 4 metropolitan Connecticut areas, 1998. J Infect Dis 2001; 184:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10263/abstract/17\">",
"      Burton DC, Edwards JR, Horan TC, et al. Methicillin-resistant Staphylococcus aureus central line-associated bloodstream infections in US intensive care units, 1997-2007. JAMA 2009; 301:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10263/abstract/18\">",
"      Warshawsky B, Hussain Z, Gregson DB, et al. Hospital- and community-based surveillance of methicillin-resistant Staphylococcus aureus: previous hospitalization is the major risk factor. Infect Control Hosp Epidemiol 2000; 21:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10263/abstract/19\">",
"      Herold BC, Immergluck LC, Maranan MC, et al. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA 1998; 279:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10263/abstract/20\">",
"      Centers for Disease Control and Prevention (CDC). Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus &mdash; Minnesota and North Dakota, 1997-1999. MMWR Morb Mortal Wkly Rep 1999; 48:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10263/abstract/21\">",
"      Collignon P, Gosbell I, Vickery A, et al. Community-acquired meticillin-resistant Staphylococcus aureus in Australia. Australian Group on Antimicrobial Resistance. Lancet 1998; 352:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10263/abstract/22\">",
"      Naimi TS, LeDell KH, Como-Sabetti K, et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 2003; 290:2976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10263/abstract/23\">",
"      Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006; 355:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10263/abstract/24\">",
"      Centers for Disease Control and Prevention (CDC). Staphylococcus aureus with reduced susceptibility to vancomycin--Illinois, 1999. MMWR Morb Mortal Wkly Rep 2000; 48:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10263/abstract/25\">",
"      Chambers HF, Korzeniowski OM, Sande MA. Staphylococcus aureus endocarditis: clinical manifestations in addicts and nonaddicts. Medicine (Baltimore) 1983; 62:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10263/abstract/26\">",
"      Hecht SR, Berger M. Right-sided endocarditis in intravenous drug users. Prognostic features in 102 episodes. Ann Intern Med 1992; 117:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10263/abstract/27\">",
"      Maradona JA, Carton JA, L&oacute;pez-Alonso J, et al. Comparative study of community versus hospital-acquired Staphylococcus aureus bacteraemia. Eur J Med 1992; 1:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10263/abstract/28\">",
"      Berman DS, Schaefler S, Simberkoff MS, Rahal JJ. Staphylococcus aureus colonization in intravenous drug abusers, dialysis patients, and diabetics. J Infect Dis 1987; 155:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10263/abstract/29\">",
"      Craven DE, Rixinger AI, Goularte TA, McCabe WR. Methicillin-resistant Staphylococcus aureus bacteremia linked to intravenous drug abusers using a \"shooting gallery\". Am J Med 1986; 80:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10263/abstract/30\">",
"      Tuazon CU, Sheagren JN. Increased rate of carriage of Staphylococcus aureus among narcotic addicts. J Infect Dis 1974; 129:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10263/abstract/31\">",
"      Quagliarello B, Cespedes C, Miller M, et al. Strains of Staphylococcus aureus obtained from drug-use networks are closely linked. Clin Infect Dis 2002; 35:671.",
"     </a>",
"    </li>",
"    <li>",
"     Moreillon P, Que YA, Glauser MP. Staphylococcus aureus (including staphylococcal toxic shock). In: Principles and Practice of Infectious Diseases,, 6th ed, Mandell GL, Bennett JE, Dolin R (Eds), Churchill Livingstone, Philadelphia 2005. p.2321.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10263/abstract/33\">",
"      Jacobsson G, Dashti S, Wahlberg T, Andersson R. The epidemiology of and risk factors for invasive Staphylococcus aureus infections in western Sweden. Scand J Infect Dis 2007; 39:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10263/abstract/34\">",
"      Yu VL, Goetz A, Wagener M, et al. Staphylococcus aureus nasal carriage and infection in patients on hemodialysis. Efficacy of antibiotic prophylaxis. N Engl J Med 1986; 315:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10263/abstract/35\">",
"      Kirmani N, Tuazon CU, Murray HW, et al. Staphylococcus aureus carriage rate of patients receiving long-term hemodialysis. Arch Intern Med 1978; 138:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10263/abstract/36\">",
"      Wertheim HF, Vos MC, Ott A, et al. Risk and outcome of nosocomial Staphylococcus aureus bacteraemia in nasal carriers versus non-carriers. Lancet 2004; 364:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10263/abstract/37\">",
"      Holtfreter S, Roschack K, Eichler P, et al. Staphylococcus aureus carriers neutralize superantigens by antibodies specific for their colonizing strain: a potential explanation for their improved prognosis in severe sepsis. J Infect Dis 2006; 193:1275.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2139 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-190.92.87.115-0E8DCFA2F5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_1_10263=[""].join("\n");
var outline_f10_1_10263=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H190976558\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Nosocomial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Community-acquired",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Healthcare-associated community onset",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Antimicrobial resistance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Methicillin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Vancomycin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Prosthetic device",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Injection drug use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Underlying conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Nasal colonization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H190976558\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/53/8026?source=related_link\">",
"      Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37464?source=related_link\">",
"      Epidemiology, pathogenesis, and microbiology of intravascular catheter infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/31/14840?source=related_link\">",
"      Epidemiology, risk factors and microbiology of infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/13/15575?source=related_link\">",
"      Microbiology of methicillin-resistant Staphylococcus aureus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17338?source=related_link\">",
"      Prevention and control of methicillin-resistant Staphylococcus aureus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24249?source=related_link\">",
"      Treatment of Staphylococcus aureus bacteremia in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_1_10264="Performance of prehospital fibrinolysis";
var content_f10_1_10264=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Performance of prehospital fibrinolysis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/1/10264/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/1/10264/contributors\">",
"     Henderson McGinnis, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/1/10264/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/1/10264/contributors\">",
"     James Hoekstra, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/1/10264/contributors\">",
"     Freek Verheugt, MD, FACC, FESC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/1/10264/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/1/10264/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/1/10264/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H27685233\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibrinolytics are an effective reperfusion therapy for many patients with ST elevation myocardial infarction (STEMI), but they must be administered within a tight time frame [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10264/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. For each 30 minute delay to reperfusion, there is approximately a 10 percent relative increase in mortality in patients with STEMI.",
"   </p>",
"   <p>",
"    Many factors may contribute to delays in therapy, including patient education and systems issues. Patients who present with STEMI in rural locations may live far from emergency departments or catheterization laboratory facilities. In these settings, prehospital fibrinolytic therapy, administered by paramedics or other prehospital personnel prior to arrival in the emergency department, may decrease the time to reperfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10264/abstract/2-13\">",
"     2-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic describes the training, treatment protocols, and quality assurance programs needed to ensure a safe and effective prehospital fibrinolysis program. Detailed information about the medications, including fibrinolytics, used to treat STEMI, data supporting the effectiveness of prehospital fibrinolysis, and general information about the diagnosis and management of acute coronary syndrome and STEMI are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=see_link\">",
"     \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/14/25830?source=see_link\">",
"     \"Prehospital fibrinolysis (thrombolysis) for suspected acute ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=see_link\">",
"     \"Overview of the acute management of ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/43/15034?source=see_link\">",
"     \"Initial evaluation and management of suspected acute coronary syndrome in the emergency department\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H199612\">",
"    <span class=\"h1\">",
"     APPLICABILITY OF PREHOSPITAL FIBRINOLYSIS TO COMMUNITY EMS PRACTICE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple studies have demonstrated the effectiveness of prehospital fibrinolysis in reducing the time to treatment for patients with ST elevation myocardial infarction (STEMI) and improving outcomes. These studies are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/14/25830?source=see_link&amp;anchor=H3#H3\">",
"     \"Prehospital fibrinolysis (thrombolysis) for suspected acute ST elevation myocardial infarction\", section on 'Efficacy of prehospital fibrinolysis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The applicability of this approach to the practice of general community emergency medical services (EMS) has also been demonstrated in several studies [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10264/abstract/14-18\">",
"     14-18",
"    </a>",
"    ]. The ER-TIMI 19 trial included 20 EMS systems in urban, semi-urban, and rural areas in the United States and Canada [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10264/abstract/14\">",
"     14",
"    </a>",
"    ]. A straightforward training program permitted paramedical personnel working with a remote medical control physician to screen patients with suspected MI by history, physical examination, and electrocardiogram (ECG). Patients with an STEMI received fibrinolytic therapy within a median of 31 minutes after arrival of paramedical personnel in comparison to 63 minutes for in-hospital fibrinolysis in a control group.",
"   </p>",
"   <p>",
"    A similar report examined the benefit of prehospital fibrinolysis in the French EMS system [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10264/abstract/15\">",
"     15",
"    </a>",
"    ]. Of 1922 patients with STEMI presenting in November 2000, 180 (9 percent) received prehospital fibrinolysis. Mortality at one year was significantly lower among patients treated with prehospital fibrinolysis than among patients treated with either in-hospital fibrinolysis or primary percutaneous coronary intervention (6 versus 11 and 11 percent, adjusted relative risk 0.49, 95% CI 0.24-1.00).",
"   </p>",
"   <p>",
"    As community prehospital fibrinolysis likely requires a high-volume EMS system and ongoing recertification to be safe and effective, rural systems may struggle to meet performance standards. Maintaining high-volume may be difficult even in urban settings. In a report of two EMS studies performed in Tennessee and Ohio, fewer than 5 percent of patients presenting with chest pain were found to be candidates for fibrinolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10264/abstract/19\">",
"     19",
"    </a>",
"    ]. In addition, only 60 percent of field treatment decisions by emergency physicians using transmitted 12-lead ECGs were accurate. A decline in paramedic skills was noted because of infrequent administration of the fibrinolytic agent.",
"   </p>",
"   <p>",
"    Other obstacles in addition to volume may exist in rural areas [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10264/abstract/20\">",
"     20",
"    </a>",
"    ]. At least one provider on each ambulance must be trained in ECG interpretation and fibrinolytic administration, and frequent oversight and",
"    <span class=\"nowrap\">",
"     retraining/re-credentialing",
"    </span>",
"    is needed to maintain competency. Online medical control is needed to administer fibrinolysis appropriately and many rural EMS systems employ off line control. Finally, the cost of fibrinolytics can be substantial, especially in settings where numerous ambulances require the drugs to be stocked, but use is infrequent. For these reasons, some rural EMS systems have been reluctant to adopt prehospital fibrinolysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27685240\">",
"    <span class=\"h1\">",
"     NECESSARY EQUIPMENT AND CAPABILITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;EMS systems that employ prehospital fibrinolysis must be able to identify the patient with an ST elevation myocardial infarction (STEMI), notify the receiving hospital of their arrival, and treat the patient en route to the hospital. Capabilities vary from system to system, and from country to country, but certain basic capabilities are required:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Prehospital 12 lead electrocardiogram (ECG)",
"      </strong>",
"      &ndash; Paramedics must be trained to obtain a prehospital ECG rapidly and efficiently, interpret that ECG (with the help of computerized algorithms), and correlate the ECG with the patient&rsquo;s presenting symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?10/1/10264/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Prehospital ECG transmission capability",
"      </strong>",
"      &ndash; Prehospital 12 lead ECGs are usually transmitted to a receiving hospital or to the prehospital medical direction facility where an emergency physician or cardiologist can assess them. Receiving facilities may have &ldquo;on-line&rdquo; control, in which the medical director interprets the ECG independently, discusses the patient with the prehospital provider, agrees or disagrees with the paramedic reading, and orders the administration of fibrinolytics. Other EMS systems have &ldquo;off-line&rdquo; control, which allows the prehospital provider to interpret the ECG independently and administer fibrinolysis according to a protocol. Such is the case in many European countries and in Israel, where physicians are often present in the ambulance [",
"      <a class=\"abstract\" href=\"UTD.htm?10/1/10264/abstract/22\">",
"       22",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      ECGs are transmitted using either analog or digital technology via land lines or cell phones. The ECG can also be transmitted using some wireless handheld electronic devices equipped with a camera by using a photograph of the ECG.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Fibrinolysis checklist",
"      </strong>",
"      &ndash; Paramedics or prehospital providers must review the indications and contraindications to fibrinolytics to ensure that the patient meets eligibility criteria",
"      <strong>",
"       before",
"      </strong>",
"      administering the medication. The use of an explicit checklist ensures the best patient outcomes and minimizes medical and legal risks from inappropriate treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?10/1/10264/abstract/23\">",
"       23",
"      </a>",
"      ]. We have attached a table listing the absolute and relative contraindications to fibrinolysis in the setting of STEMI and a separate flow sheet for the administration of fibrinolytic therapy that is used by paramedics at the author&rsquo;s home institution (",
"      <a class=\"graphic graphic_table graphicRef68784 \" href=\"UTD.htm?23/16/23820\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_algorithm graphicRef78120 \" href=\"UTD.htm?41/39/42618\">",
"       algorithm 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Prehospital STEMI treatment protocol",
"      </strong>",
"      &ndash; Intravenous (IV) access and continuous cardiac monitoring should be in place before fibrinolytic medications are given. Fibrinolytics are given along with other indicated therapies such as oxygen and medications including nitrates, beta blockers, antiplatelet agents (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      , P2Y12 receptor blockers), and anticoagulants (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"       bivalirudin",
"      </a>",
"      , or low molecular weight heparin). Essential clinical information about these medications, including doses and contraindications, must be included in the prehospital STEMI and fibrinolysis treatment protocol [",
"      <a class=\"abstract\" href=\"UTD.htm?10/1/10264/abstract/3,4,12,24-32\">",
"       3,4,12,24-32",
"      </a>",
"      ]. As an example, the attached flow sheet for chest pain is used by the paramedics at the author&rsquo;s home institution (",
"      <a class=\"graphic graphic_algorithm graphicRef57981 \" href=\"UTD.htm?40/60/41930\">",
"       algorithm 2",
"      </a>",
"      ). A separate table summarizing the acute treatment of acute coronary syndrome is provided, as well as links to topics describing the medical management of STEMI (",
"      <a class=\"graphic graphic_table graphicRef75032 \" href=\"UTD.htm?33/25/34206\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=see_link\">",
"       \"Overview of the acute management of ST elevation myocardial infarction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/57/5018?source=see_link\">",
"       \"Anticoagulant therapy in acute ST elevation myocardial infarction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=see_link\">",
"       \"Antiplatelet agents in acute ST elevation myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Destination protocols",
"      </strong>",
"      &ndash; Patients treated with fibrinolysis in the prehospital setting should be transported to facilities capable of providing advanced cardiac care, including percutaneous coronary intervention (PCI), especially in the case of failed fibrinolysis, and the management of complications from STEMI [",
"      <a class=\"abstract\" href=\"UTD.htm?10/1/10264/abstract/3,25,27\">",
"       3,25,27",
"      </a>",
"      ]. Patients who are not eligible for prehospital fibrinolysis are generally transported to the closest PCI-capable facility for primary PCI. This may include air transport, if indicated. It is imperative to have destination protocols and transport capabilities prepared in advance, prior to the implementation of any prehospital fibrinolysis protocol. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8634?source=see_link\">",
"       \"Management of failed fibrinolysis (thrombolysis) or threatened reocclusion in acute ST elevation myocardial infarction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/42/34473?source=see_link\">",
"       \"Percutaneous coronary intervention after fibrinolysis for acute ST elevation myocardial infarction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39225?source=see_link\">",
"       \"Mechanical complications of acute myocardial infarction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=see_link\">",
"       \"Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to the capabilities described above, community support is essential for any successful prehospital fibrinolysis program. All participants, including hospital administrators, EMS directors, emergency and cardiology department clinicians and support personnel, and paramedics must be fully informed and committed to the program&rsquo;s success.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27685290\">",
"    <span class=\"h1\">",
"     REQUIREMENTS OF PREHOSPITAL PROVIDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of fibrinolytics in the prehospital setting is held to the same standards as those for the emergency department (ED). As such, quality control and training are of the utmost importance. At least one member of a paramedic-EMT or paramedic-paramedic team giving such therapy must have demonstrated proficiency in ECG interpretation and administration of fibrinolytic medication. Although these proficiencies are certified locally (eg, by the hospital), the process of demonstrating proficiency must be formalized.",
"   </p>",
"   <p>",
"    <br/>",
"    STEMI patients must be rapidly identified by 12 lead ECG to determine if they are candidates for fibrinolysis. Therefore, paramedics must be proficient in obtaining, interpreting, and transmitting an ECG rapidly. We recommend that a paramedic administering fibrinolytics have at least one year of experience and have successfully completed a 50 hour course on 12 lead ECG interpretation and fibrinolytic administration, including a written examination. In addition, the paramedic should observe fibrinolytics being administered to three patients before giving the medication themselves. Time spent in the ED and catheterization labs of local referral hospitals helps paramedics familiarize themselves with the staff and capabilities of these departments.",
"   </p>",
"   <p>",
"    In addition to interpreting the ECG, completing the fibrinolysis checklist, and administering fibrinolytics and related medications, prehospital providers must be able to obtain important information about the patient and convey it to their medical control physicians prior to giving fibrinolytics. Such information includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patient age, gender",
"     </li>",
"     <li>",
"      Chief complaint (usually chest pain)",
"     </li>",
"     <li>",
"      Characteristics of chief complaint (eg, onset, duration, quality, provocative &amp; palliative factors, associated symptoms)",
"     </li>",
"     <li>",
"      Vital signs (blood pressure, pulse rate, respiratory rate, oxygen saturation)",
"     </li>",
"     <li>",
"      Signs of decompensated heart failure",
"     </li>",
"     <li>",
"      Pertinent cardiac and medical history, medications, drug allergies",
"     </li>",
"     <li>",
"      Estimated time to arrival at the receiving facility",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The ability to obtain and understand this information, report it accurately, and discuss it in real time extends beyond typical paramedic capabilities and requires additional training and experience. Therefore, the education and testing of paramedics participating in a prehospital fibrinolysis program should encompass the full breadth of chest pain evaluation, in addition to ECG interpretation and administration of treatments. Practical testing involving simulated patients with STEMI is necessary to demonstrate competency. Attached is a checklist used at the author&rsquo;s home institution to assess paramedic performance in prehospital fibrinolysis competency testing (",
"    <a class=\"graphic graphic_table graphicRef63223 \" href=\"UTD.htm?41/29/42461\">",
"     table 3",
"    </a>",
"    ). &nbsp;",
"   </p>",
"   <p>",
"    It is important that paramedics certified to provide prehospital fibrinolysis participate in periodic classes and reevaluations to ensure skill retention. We suggest quarterly classes on ECG interpretation and annual retesting to demonstrate proficiency. Within the author&rsquo;s EMS service, the ability of the crew to administer prehospital fibrinolytics serves as a motivational tool. Not all paramedics are certified to provide this therapy and it gives paramedics a coveted goal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5275312\">",
"    <span class=\"h1\">",
"     PATIENT ELIGIBILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reperfusion should be attempted as soon as possible in all patients diagnosed with an acute ST-elevation myocardial infarction (STEMI) who present within an appropriate time frame. Percutaneous coronary intervention (PCI) is generally the preferred method of reperfusion for patients with STEMI. Patients in facilities without timely access to PCI may require fibrinolytic therapy. Such patients must be screened for absolute and relative contraindications as fibrinolysis carries a risk of severe bleeding, including intracranial hemorrhage, when given inappropriately. A table listing the absolute and relative contraindications to fibrinolysis in the setting of STEMI is provided (",
"    <a class=\"graphic graphic_table graphicRef68784 \" href=\"UTD.htm?23/16/23820\">",
"     table 1",
"    </a>",
"    ). Selection of the appropriate therapy for STEMI, the contraindications and risks associated with fibrinolysis, and the efficacy of the medications used for fibrinolysis are all reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/31/37369?source=see_link\">",
"     \"Selecting a reperfusion strategy for acute ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=see_link\">",
"     \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7786?source=see_link\">",
"     \"Fibrinolytic (thrombolytic) agents in acute ST elevation myocardial infarction: Markers of efficacy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/27/14778?source=see_link\">",
"     \"Characteristics of fibrinolytic (thrombolytic) agents and clinical trials in acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27685323\">",
"    <span class=\"h1\">",
"     MEDICATION ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prehospital clinicians (eg, paramedics) work in a difficult setting where speed and efficiency are of the utmost importance. As such, pharmacologic therapies must sometimes be modified to make dosing as simple as possible and maximize the speed of administration. In some cases, medications not typically used in the hospital must be included in the prehospital formulary. A table summarizing the medications used in the acute treatment of acute coronary syndrome (STEMI or non-STEMI) is provided (",
"    <a class=\"graphic graphic_table graphicRef75032 \" href=\"UTD.htm?33/25/34206\">",
"     table 2",
"    </a>",
"    ). Below we list important medications given to patients being treated with fibrinolytics in the prehospital setting for STEMI and some of the ways in which they are modified:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Antiplatelet agents",
"      </strong>",
"      (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=see_link\">",
"       \"Antiplatelet agents in acute ST elevation myocardial infarction\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      is usually given as two to four chewable baby aspirin (ie, 162 to 325 mg) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/1/10264/abstract/31\">",
"       31",
"      </a>",
"      ]. If the patient cannot swallow, IV aspirin may be used if available.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       Clopidogrel",
"      </a>",
"      &ndash; Clopidogrel should be included among the medications available in any ambulance that administers prehospital fibrinolysis, and whenever possible we suggest giving clopidogrel (300 mg by mouth) as part of the prehospital treatment for STEMI. If this is not possible, clopidogrel can be given when the patient arrives at the hospital or the catheterization laboratory [",
"      <a class=\"abstract\" href=\"UTD.htm?10/1/10264/abstract/29-31\">",
"       29-31",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=see_link&amp;anchor=H16#H16\">",
"       \"Antiplatelet agents in acute ST elevation myocardial infarction\", section on 'With fibrinolytic therapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Antithrombotic therapy",
"      </strong>",
"      (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/57/5018?source=see_link\">",
"       \"Anticoagulant therapy in acute ST elevation myocardial infarction\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       Heparin",
"      </a>",
"      <strong>",
"       or low molecular weight heparin",
"      </strong>",
"      &ndash; Low molecular weight heparin is the preferred antithrombin agent in the prehospital setting due to its ease of administration (IV bolus and subcutaneous dosing). We prefer",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      30 mg IV push (or 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      subcutaneous), administered with fibrinolysis. Patients over 75 years old receive enoxaparin 0.75 mg subcutaneous with no IV bolus. As an alternative, heparin can be administered as a weight based IV bolus without a subsequent infusion (maximum bolus dose is 4000 units) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/1/10264/abstract/3,4,24,26-28\">",
"       3,4,24,26-28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Nitroglycerin",
"      </strong>",
"      <strong>",
"       sublingual tablet or spray",
"      </strong>",
"      &ndash; Sublingual",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"      is routinely given by prehospital providers. Medications requiring IV infusions are often omitted in the prehospital setting because they delay transport and require special equipment. However, if time and capability permit, IV nitroglycerine infusions may be initiated and titrated to pain and blood pressure en route to the hospital. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24566?source=see_link\">",
"       \"Nitrates in the management of acute coronary syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Morphine",
"      </strong>",
"      <strong>",
"      </strong>",
"      ���",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       Morphine sulfate",
"      </a>",
"      (2 to 4 mg slow IV push) can be given to patients with persistent discomfort or anxiety every 5 to 15 minutes. Smaller doses and larger intervals may be needed in patients with hypotension.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Fibrinolytic therapy",
"      </strong>",
"      &ndash; Fibrinolytics that can be given as an IV bolus, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/39/14966?source=see_link\">",
"       tenecteplase",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/25/30101?source=see_link\">",
"       reteplase",
"      </a>",
"      , are preferred over tPA due to ease of administration. Reteplase can be given as 10 mg in the prehospital setting and another 10 mg upon arrival at the hospital. Tenecteplase can be given as a weight based IV bolus in the prehospital setting, but requires documentation of the patient&rsquo;s weight (obtained by history, not measurement). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=see_link\">",
"       \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/27/14778?source=see_link\">",
"       \"Characteristics of fibrinolytic (thrombolytic) agents and clinical trials in acute ST elevation myocardial infarction\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Either fibrinolytic agent must be refrigerated. The costs of refrigeration and expired vials of fibrinolytic medications can have profound financial implications for an EMS system [",
"      <a class=\"abstract\" href=\"UTD.htm?10/1/10264/abstract/27,28\">",
"       27,28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5275791\">",
"    <span class=\"h1\">",
"     EFFICACY AND COMPLICATIONS OF FIBRINOLYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effectiveness of fibrinolytic therapy in the treatment of STEMI varies depending upon multiple factors, including the time from symptom onset to therapy, the fibrinolytic medication selected, and the time delay to subsequent PCI if needed, but overall when given appropriately the treatment is effective in approximately 70 percent of cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=see_link\">",
"     \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/27/14778?source=see_link\">",
"     \"Characteristics of fibrinolytic (thrombolytic) agents and clinical trials in acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several clinical findings suggest that fibrinolytic therapy has been effective. These include relief of symptoms, resolution of ST segment elevations, and possibly the development of reperfusion arrhythmias, including accelerated idioventricular rhythm. A detailed discussion of the efficacy of fibrinolytic therapy is found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7786?source=see_link\">",
"     \"Fibrinolytic (thrombolytic) agents in acute ST elevation myocardial infarction: Markers of efficacy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bleeding is the primary complication of fibrinolytic therapy and hemorrhagic stroke is the greatest concern. Thus, paramedics must screen patients carefully for contraindications to fibrinolysis and monitor patients closely following administration for signs of stroke. Common signs include deterioration in mental status, headache, nausea and vomiting, or a sudden rise in blood pressure. Other potential complications include allergic reactions (seen primarily with streptokinase treatment). The complications associated with fibrinolysis are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=see_link&amp;anchor=H69243077#H69243077\">",
"     \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\", section on 'Complications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=see_link&amp;anchor=H25#H25\">",
"     \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\", section on 'Contraindications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Following prehospital fibrinolysis, some patients experience a recurrence of symptoms and signs of STEMI, suggesting reocclusion of the involved coronary artery. This may include recurrent or new ST segment elevations. Recurrence is best treated with percutaneous coronary intervention (PCI). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8634?source=see_link\">",
"     \"Management of failed fibrinolysis (thrombolysis) or threatened reocclusion in acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27685330\">",
"    <span class=\"h1\">",
"     QUALITY ASSURANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Quality assurance and quality improvement programs are essential if prehospital fibrinolysis is to be successful. General information about quality measures is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/49/37657?source=see_link\">",
"     \"Measuring quality in hospitals in the United States: Core process measures\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since STEMI treated with fibrinolysis is an infrequent occurrence for any single EMS system, it is important to use each case as a teaching tool. At the author&rsquo;s institution, each case is closely reviewed, with careful attention paid to the performance of and the time required for each of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Obtaining, interpreting, and transmitting the ECG",
"     </li>",
"     <li>",
"      Completing the fibrinolysis checklist",
"     </li>",
"     <li>",
"      Assessing the patient and discussing the case with the medical control physician",
"     </li>",
"     <li>",
"      Administering fibrinolytic medication",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patient outcome is closely followed as part of quality assurance. Review includes both patients treated with prehospital fibrinolytics and those with STEMI who do not receive prehospital fibrinolytics, and in the author&rsquo;s institution is performed by the shift supervisor, paramedic training officer, and physician medical directors. In addition, the dosing of all medications is reviewed on a regular basis; all medications in the ambulance are regularly checked and clearly labeled.",
"   </p>",
"   <p>",
"    We recommend that the ECGs of prospective candidates for fibrinolysis be reviewed in real time prior to fibrinolysis by the medical control physician at the receiving emergency department or hospital in order to avoid misinterpretation. This is particularly important for those patients with ECGs that are difficult to interpret or have equivocal findings, such as bundle branch blocks or left ventricular hypertrophy. This approach has helped us avoid giving fibrinolytics to patients without a STEMI. In addition, our EMS crews regularly review ECGs after the case to improve their interpretation skills.",
"   </p>",
"   <p>",
"    One way to reduce the number of missed STEMIs in patients with atypical symptoms (eg, dyspnea, weakness) is to perform a 12 lead ECG on every patient with a relevant chief complaint. This may not be practical in some instances, and we allow our EMS crews some latitude in deciding whether to obtain an ECG, but our chest pain protocol includes liberal criteria for obtaining an ECG. Atypical symptoms associated with acute coronary syndrome are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/43/15034?source=see_link&amp;anchor=H14#H14\">",
"     \"Initial evaluation and management of suspected acute coronary syndrome in the emergency department\", section on 'Atypical symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27685349\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Appropriately designed and implemented programs for prehospital fibrinolysis can reduce delays in providing definitive care and improve outcomes for some patients with ST elevation myocardial infarction (STEMI), particularly those without ready access to facilities capable of performing percutaneous coronary intervention. (See",
"      <a class=\"local\" href=\"#H199612\">",
"       'Applicability of prehospital fibrinolysis to community EMS practice'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      EMS systems that employ prehospital fibrinolysis must be able to identify the patient with an STEMI, communicate with the receiving hospital, and treat the patient en route. This requires specific equipment and capabilities including: well-trained paramedics, expert physician oversight, electrocardiogram interpretation and transmission, communications equipment and personnel, a fibrinolysis checklist and treatment protocol, a destination protocol, and necessary medications. (See",
"      <a class=\"local\" href=\"#H27685240\">",
"       'Necessary equipment and capabilities'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H27685290\">",
"       'Requirements of prehospital providers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Candidates for fibrinolysis must be screened for absolute and relative contraindications, as fibrinolysis carries a risk of severe bleeding, including intracranial hemorrhage, when given inappropriately (",
"      <a class=\"graphic graphic_table graphicRef68784 \" href=\"UTD.htm?23/16/23820\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5275312\">",
"       'Patient eligibility'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pharmacologic therapies must sometimes be modified for use in the prehospital setting. Issues related to specific medications necessary for prehospital fibrinolysis are discussed in the text. (See",
"      <a class=\"local\" href=\"#H27685323\">",
"       'Medication issues'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Quality assurance is an essential aspect of any successful prehospital fibrinolysis program. (See",
"      <a class=\"local\" href=\"#H27685330\">",
"       'Quality assurance'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10264/abstract/1\">",
"      A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators. N Engl J Med 1997; 336:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10264/abstract/2\">",
"      Boden WE, Eagle K, Granger CB. Reperfusion strategies in acute ST-segment elevation myocardial infarction: a comprehensive review of contemporary management options. J Am Coll Cardiol 2007; 50:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10264/abstract/3\">",
"      Welsh RC, Goldstein P, Adgey J, et al. Variations in pre-hospital fibrinolysis process of care: insights from the Assessment of the Safety and Efficacy of a New Thrombolytic 3 Plus international acute myocardial infarction pre-hospital care survey. Eur J Emerg Med 2004; 11:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10264/abstract/4\">",
"      Wallentin L, Goldstein P, Armstrong PW, et al. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation 2003; 108:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10264/abstract/5\">",
"      Chamberlain D. Pre-hospital thrombolysis. Curr Opin Anaesthesiol 1999; 12:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10264/abstract/6\">",
"      Boersma E, Maas AC, Deckers JW, Simoons ML. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet 1996; 348:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10264/abstract/7\">",
"      Schofer J, B&uuml;ttner J, Geng G, et al. Prehospital thrombolysis in acute myocardial infarction. Am J Cardiol 1990; 66:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10264/abstract/8\">",
"      Linderer T, Schr&ouml;der R, Arntz R, et al. Prehospital thrombolysis: beneficial effects of very early treatment on infarct size and left ventricular function. J Am Coll Cardiol 1993; 22:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10264/abstract/9\">",
"      Rawles JM. Quantification of the benefit of earlier thrombolytic therapy: five-year results of the Grampian Region Early Anistreplase Trial (GREAT). J Am Coll Cardiol 1997; 30:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10264/abstract/10\">",
"      Coccolini S, Berti G, Maresta A. The magnitude of the benefit from preCCU thrombolysis in acute myocardial infarction: a long term follow up. Int J Cardiol 1998; 65 Suppl 1:S49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10264/abstract/11\">",
"      Brouwer MA, Martin JS, Maynard C, et al. Influence of early prehospital thrombolysis on mortality and event-free survival (the Myocardial Infarction Triage and Intervention [MITI] Randomized Trial). MITI Project Investigators. Am J Cardiol 1996; 78:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10264/abstract/12\">",
"      Grijseels EW, Bouten MJ, Lenderink T, et al. Pre-hospital thrombolytic therapy with either alteplase or streptokinase. Practical applications, complications and long-term results in 529 patients. Eur Heart J 1995; 16:1833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10264/abstract/13\">",
"      Kennedy JW. 50th anniversary historical article. Thrombolytic therapy in acute myocardial infarction. J Am Coll Cardiol 1999; 33:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10264/abstract/14\">",
"      Morrow DA, Antman EM, Sayah A, et al. Evaluation of the time saved by prehospital initiation of reteplase for ST-elevation myocardial infarction: results of The Early Retavase-Thrombolysis in Myocardial Infarction (ER-TIMI) 19 trial. J Am Coll Cardiol 2002; 40:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10264/abstract/15\">",
"      Danchin N, Blanchard D, Steg PG, et al. Impact of prehospital thrombolysis for acute myocardial infarction on 1-year outcome: results from the French Nationwide USIC 2000 Registry. Circulation 2004; 110:1909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10264/abstract/16\">",
"      Pedley DK, Bissett K, Connolly EM, et al. Prospective observational cohort study of time saved by prehospital thrombolysis for ST elevation myocardial infarction delivered by paramedics. BMJ 2003; 327:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10264/abstract/17\">",
"      Bj&ouml;rklund E, Stenestrand U, Lindb&auml;ck J, et al. Pre-hospital thrombolysis delivered by paramedics is associated with reduced time delay and mortality in ambulance-transported real-life patients with ST-elevation myocardial infarction. Eur Heart J 2006; 27:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10264/abstract/18\">",
"      Welsh RC, Travers A, Senaratne M, et al. Feasibility and applicability of paramedic-based prehospital fibrinolysis in a large North American center. Am Heart J 2006; 152:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10264/abstract/19\">",
"      Gibler WB, Kereiakes DJ, Dean EN, et al. Prehospital diagnosis and treatment of acute myocardial infarction: a north-south perspective. The Cincinnati Heart Project and the Nashville Prehospital TPA Trial. Am Heart J 1991; 121:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10264/abstract/20\">",
"      Schull MJ, Vaillancourt S, Donovan L, et al. Underuse of prehospital strategies to reduce time to reperfusion for ST-elevation myocardial infarction patients in 5 Canadian provinces. CJEM 2009; 11:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10264/abstract/21\">",
"      Myers RB. Prehospital management of acute myocardial infarction: Electrocardiogram acquisition and interpretation, and thrombolysis by prehospital care providers. Can J Cardiol 1998; 14:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10264/abstract/22\">",
"      Clemmensen P, Sejersten M, Sillesen M, et al. Diversion of ST-elevation myocardial infarction patients for primary angioplasty based on wireless prehospital 12-lead electrocardiographic transmission directly to the cardiologist's handheld computer: a progress report. J Electrocardiol 2005; 38:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10264/abstract/23\">",
"      Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Lancet 1994; 343:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10264/abstract/24\">",
"      Antman EM, Morrow DA, McCabe CH, et al. Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25). Am Heart J 2005; 149:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10264/abstract/25\">",
"      Gibson CM, Murphy SA, Montalescot G, et al. Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial. J Am Coll Cardiol 2007; 49:2238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10264/abstract/26\">",
"      Gabriel RS, White HD. ExTRACT-TIMI 25 trial: clarifying the role of enoxaparin in patients with ST-elevation myocardial infarction receiving fibrinolysis. Expert Rev Cardiovasc Ther 2007; 5:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10264/abstract/27\">",
"      Sinnaeve PR, Huang Y, Bogaerts K, et al. Age, outcomes, and treatment effects of fibrinolytic and antithrombotic combinations: findings from Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT)-3 and ASSENT-3 PLUS. Am Heart J 2006; 152:684.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10264/abstract/28\">",
"      Mehta RH, Alexander JH, Van de Werf F, et al. Relationship of incorrect dosing of fibrinolytic therapy and clinical outcomes. JAMA 2005; 293:1746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10264/abstract/29\">",
"      Sabatine MS, McCabe CH, Gibson CM, Cannon CP. Design and rationale of Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 trial. Am Heart J 2005; 149:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10264/abstract/30\">",
"      Sabatine MS, Cannon CP, Gibson CM, et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 2005; 294:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10264/abstract/31\">",
"      Verheugt FW, Montalescot G, Sabatine MS, et al. Prehospital fibrinolysis with dual antiplatelet therapy in ST-elevation acute myocardial infarction: a substudy of the randomized double blind CLARITY-TIMI 28 trial. J Thromb Thrombolysis 2007; 23:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10264/abstract/32\">",
"      Smalling RW, Giesler GM, Julapalli VR, et al. Pre-hospital reduced-dose fibrinolysis coupled with urgent percutaneous coronary intervention reduces time to reperfusion and improves angiographic perfusion score compared with prehospital fibrinolysis alone or primary percutaneous coronary intervention: results of the PATCAR Pilot Trial. J Am Coll Cardiol 2007; 50:1612.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13865 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-C175512C90-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_1_10264=[""].join("\n");
var outline_f10_1_10264=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27685349\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27685233\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H199612\">",
"      APPLICABILITY OF PREHOSPITAL FIBRINOLYSIS TO COMMUNITY EMS PRACTICE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27685240\">",
"      NECESSARY EQUIPMENT AND CAPABILITIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27685290\">",
"      REQUIREMENTS OF PREHOSPITAL PROVIDERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5275312\">",
"      PATIENT ELIGIBILITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27685323\">",
"      MEDICATION ISSUES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5275791\">",
"      EFFICACY AND COMPLICATIONS OF FIBRINOLYSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27685330\">",
"      QUALITY ASSURANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27685349\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/13865\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13865|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?41/39/42618\" title=\"algorithm 1\">",
"      Prehospital thrombolytic therapy flow sheet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?40/60/41930\" title=\"algorithm 2\">",
"      Prehospital chest pain STEMI flow sheets",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13865|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/16/23820\" title=\"table 1\">",
"      Contraindications to fibrinolytic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/25/34206\" title=\"table 2\">",
"      Rapid overview ACS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/29/42461\" title=\"table 3\">",
"      Paramedic thrombolysis examination checklist",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/57/5018?source=related_link\">",
"      Anticoagulant therapy in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=related_link\">",
"      Antiplatelet agents in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/27/14778?source=related_link\">",
"      Characteristics of fibrinolytic (thrombolytic) agents and clinical trials in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=related_link\">",
"      Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7786?source=related_link\">",
"      Fibrinolytic (thrombolytic) agents in acute ST elevation myocardial infarction: Markers of efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=related_link\">",
"      Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/43/15034?source=related_link\">",
"      Initial evaluation and management of suspected acute coronary syndrome in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8634?source=related_link\">",
"      Management of failed fibrinolysis (thrombolysis) or threatened reocclusion in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/49/37657?source=related_link\">",
"      Measuring quality in hospitals in the United States: Core process measures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39225?source=related_link\">",
"      Mechanical complications of acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24566?source=related_link\">",
"      Nitrates in the management of acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=related_link\">",
"      Overview of the acute management of ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/42/34473?source=related_link\">",
"      Percutaneous coronary intervention after fibrinolysis for acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/14/25830?source=related_link\">",
"      Prehospital fibrinolysis (thrombolysis) for suspected acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/31/37369?source=related_link\">",
"      Selecting a reperfusion strategy for acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_1_10265="Clinical manifestations, diagnosis, and treatment of human herpesvirus-6 infection in adults";
var content_f10_1_10265=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations, diagnosis, and treatment of human herpesvirus-6 infection in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/1/10265/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/1/10265/contributors\">",
"     Cecile Tremblay, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/1/10265/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/1/10265/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/1/10265/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/1/10265/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/1/10265/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human herpesvirus 6 (HHV-6) was first isolated and characterized from patients with lymphoproliferative disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10265/abstract/1\">",
"     1",
"    </a>",
"    ] and was originally named human B-lymphotropic virus. Its name was changed to human herpesvirus 6 as its tropism was further characterized [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10265/abstract/2\">",
"     2",
"    </a>",
"    ]. Like most herpesviruses, HHV-6 may remain latent in certain host cells after primary infection, but can be reactivated in immunocompromised patients.",
"   </p>",
"   <p>",
"    The clinical manifestations, diagnosis, and treatment of HHV-6 infection in adults will be presented here. The virology, pathogenesis, and epidemiology of HHV-6 infection, as well as clinical issues in children, are presented separately; HHV-6 infection in hematopoietic cell transplant recipients is also discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/14/40167?source=see_link\">",
"     \"Virology, pathogenesis, and epidemiology of human herpesvirus 6 infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31577?source=see_link\">",
"     \"Human herpesvirus 6 infection in children: Clinical manifestations; diagnosis; and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/40/30346?source=see_link\">",
"     \"Human herpesvirus 6 infection in hematopoietic cell transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3555976\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Immunocompetent hosts",
"    </span>",
"    &nbsp;&mdash;&nbsp;HHV-6 infections usually occur during childhood and result in generally mild, self-limited illnesses. Possible disease associations with HHV-6 in immunocompetent adults are not proven other than a few cases of primary infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31577?source=see_link\">",
"     \"Human herpesvirus 6 infection in children: Clinical manifestations; diagnosis; and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h3\">",
"     Primary infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary infection in adults is rare. However, a mononucleosis-like syndrome of varying severity with prolonged lymphadenopathy has been described in association with HHV-6 seroconversion in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10265/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Three adults with serologic evidence of HHV-6 infection had mild illnesses in association with bilateral, nontender, anterior, and posterior lymphadenopathy, which persisted for up to three months [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10265/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clear confirmation of the diagnosis was documented in a study of two immunocompetent adults with a mono-like illness in whom lymph node biopsies revealed intranuclear and cytoplasmic inclusions in CD4+ T-cells that were positive for HHV-6 antigen by immunohistochemistry [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10265/abstract/5\">",
"     5",
"    </a>",
"    ]. Polymerase chain reaction techniques and DNA sequencing confirmed the virus as HHV-6.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Encephalitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Encephalitis of variable severity has been associated rarely with HHV-6 infection in immunocompetent patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10265/abstract/6-9\">",
"     6-9",
"    </a>",
"    ]. Clinical presentations have included altered level of consciousness, seizures, psychosis, acute cerebellar ataxia, and focal neurological signs (ie, cranial nerve deficits or hemiparesis) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10265/abstract/6,7,10,11\">",
"     6,7,10,11",
"    </a>",
"    ]. Neurologic outcomes have varied from full recovery to death. Most cases are believed to represent reactivation disease, since primary infection in adults is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10265/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of 138 patients with encephalitis of unknown etiology, HHV-6 DNA was found in the CSF of nine patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10265/abstract/6\">",
"     6",
"    </a>",
"    ]. The CSF profile in HHV-6 encephalitis is notable for the presence of a lymphocytic pleocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10265/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Encephalitis has also been described in immunocompromised hosts (eg, transplant recipients). (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Transplant recipients'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/40/30346?source=see_link&amp;anchor=H358774586#H358774586\">",
"     \"Human herpesvirus 6 infection in hematopoietic cell transplant recipients\", section on 'HHV-6 encephalitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Mesial temporal lobe epilepsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;HHV-6 has been associated with mesial temporal lobe epilepsy (MTLE). HHV-6 DNA was recovered from brain biopsies from patients with MTLE more frequently than in controls, suggesting a pathogenic effect of the virus [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10265/abstract/13-15\">",
"     13-15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Transplant recipients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunosuppression secondary to solid organ or hematopoietic cell transplantation (HCT) may favor reactivation and replication of HHV-6, resulting in viremia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    clinical illness. Clinical syndromes associated with HHV-6 in transplant recipients include pneumonitis, hepatitis, encephalitis, and bone marrow suppression [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10265/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29433?source=see_link\">",
"     \"Infection in the solid organ transplant recipient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, these hosts are frequently coinfected with other viruses, such as cytomegalovirus, or other opportunistic agents, which complicates establishing the pathogenicity of HHV-6. The high prevalence of viral DNA in peripheral blood mononuclear cells (PBMC) of healthy controls limits the use of qualitative polymerase chain reaction (PCR) to discriminate between latency and active infection, and increases in antibody titers often occur against several viruses simultaneously.",
"   </p>",
"   <p>",
"    These difficulties were illustrated in a review of 228 consecutive HCT recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10265/abstract/17\">",
"     17",
"    </a>",
"    ]. HHV-6 viremia was documented in 42 percent of patients and in 57 percent of all clinical specimens collected. However, few clinical syndromes could be definitively attributed to HHV-6 infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Viremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;HHV-6 viremia can occur after transplantation in patients with serologic evidence of prior infection. This was illustrated in a prospective study of 65 kidney transplant recipients and their donors; all had evidence of neutralizing antibodies to HHV-6 at the time of transplant but none had viremia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10265/abstract/18\">",
"     18",
"    </a>",
"    ]. At two to four weeks after transplantation, new onset HHV-6 viremia was detected in 14 percent of recipients.",
"   </p>",
"   <p>",
"    Among liver transplant recipients, HHV-6 viremia has been associated with cytomegalovirus reactivation and symptomatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10265/abstract/19\">",
"     19",
"    </a>",
"    ]. In addition, HHV-6 has been detected in the plasma and liver of a liver transplant recipient with syncytial giant-cell hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10265/abstract/20\">",
"     20",
"    </a>",
"    ]. HHV-6 has also been recovered from gastroduodenal tissue in association with HHV-6 viremia in liver transplant recipients, although the significance of this is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10265/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HHV-6 viremia is common following HCT. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/40/30346?source=see_link\">",
"     \"Human herpesvirus 6 infection in hematopoietic cell transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Encephalitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of HHV-6 encephalitis have occurred in allogeneic hematopoietic stem cell transplant recipients (HCT), although it has also been reported rarely in solid organ transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10265/abstract/22\">",
"     22",
"    </a>",
"    ] and in immunocompetent individuals (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Encephalitis'",
"    </a>",
"    above). HHV-6 infection in HCT recipients is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/40/30346?source=see_link\">",
"     \"Human herpesvirus 6 infection in hematopoietic cell transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Pneumonitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;HHV-6 can cause pneumonitis in transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10265/abstract/17,23-25\">",
"     17,23-25",
"    </a>",
"    ]. The association between HHV-6 and pneumonitis in HCT recipients is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/40/30346?source=see_link&amp;anchor=H642415615#H642415615\">",
"     \"Human herpesvirus 6 infection in hematopoietic cell transplant recipients\", section on 'Other possible associations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Possible association with graft rejection",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h4\">",
"     Solid organ transplant",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies in renal transplant recipients have noted significant posttransplantation increases in HHV-6 antibody titers, isolation of HHV-6 from peripheral blood leukocytes, and detection of HHV-6 antigen in biopsy tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10265/abstract/18,26,27\">",
"     18,26,27",
"    </a>",
"    ]. However, most reports have failed to show a correlation with rejection among solid organ transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10265/abstract/18,26\">",
"     18,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h4\">",
"     Hematopoietic cell transplant",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among hematopoietic cell transplant (HCT) recipients, delayed bone marrow engraftment and bone marrow suppression have been associated with HHV-6 infection. There are conflicting data regarding whether HHV-6 reactivation is associated with graft-versus-host disease among HCT recipients. These issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/40/30346?source=see_link&amp;anchor=H642415594#H642415594\">",
"     \"Human herpesvirus 6 infection in hematopoietic cell transplant recipients\", section on 'Bone marrow suppression'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/40/30346?source=see_link&amp;anchor=H642415615#H642415615\">",
"     \"Human herpesvirus 6 infection in hematopoietic cell transplant recipients\", section on 'Other possible associations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3557047\">",
"    <span class=\"h1\">",
"     UNPROVEN ASSOCIATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Associations between HHV-6 and several diseases have been proposed, but not proven. These include multiple sclerosis, hepatic failure, chronic fatigue syndrome, neoplasia, and myocarditis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3557055\">",
"    <span class=\"h2\">",
"     Multiple sclerosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;HHV-6 has been implicated in both acute and chronic inflammatory demyelinating diseases. The following observations support a possible association of HHV-6 with multiple sclerosis (MS) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10265/abstract/28-32\">",
"     28-32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HHV-6 is highly neurotropic and can infect oligodendrocytes associated with MS plaques, as well as glial precursors leading to disruption of normal glial differentiation [",
"      <a class=\"abstract\" href=\"UTD.htm?10/1/10265/abstract/28,29\">",
"       28,29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      HHV-6 mRNA has been isolated in the blood in 16 percent of 105 patients with relapsing-remitting MS (RRMS) compared to none in healthy blood donors [",
"      <a class=\"abstract\" href=\"UTD.htm?10/1/10265/abstract/32\">",
"       32",
"      </a>",
"      ]. Among the patients with RRMS and isolation of HHV-6, viral load increased during periods of disease exacerbation when compared to remission. On the other hand, the use of beta interferon has been associated with a reduction in HHV-6 viral load in patients with RRMS [",
"      <a class=\"abstract\" href=\"UTD.htm?10/1/10265/abstract/33\">",
"       33",
"      </a>",
"      ]. However, HHV-6A does not seem to play an active role in secondary progressive MS [",
"      <a class=\"abstract\" href=\"UTD.htm?10/1/10265/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other reports have not supported an association between HHV-6 and MS [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10265/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. These differences may be attributable to several factors including patient selection and the techniques used. Although viruses cause a number of demyelinating neurologic disorders, the association of HHV-6 to such disorders has not been proven (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32458?source=see_link\">",
"     \"Epidemiology and clinical features of multiple sclerosis in adults\"",
"    </a>",
"    ). This controversy will be difficult to resolve in view of the ubiquitous nature of HHV-6 infection and the need to discriminate between latency and active infection [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10265/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3557062\">",
"    <span class=\"h2\">",
"     Fulminant hepatic failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;A possible role of HHV-6 as a cause of fulminant hepatic failure has been suggested [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10265/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. As an example, in one study, 32 patients who underwent liver transplantation were tested for viruses in their explanted livers [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10265/abstract/38\">",
"     38",
"    </a>",
"    ]. Fifteen of these patients had no known cause for liver failure. HHV-6 antigens were found in 12 patients (ten of whom also had HHV-6 viremia) compared with 4 of 17 patients with a known cause. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/17/2330?source=see_link\">",
"     \"Acute liver failure in adults: Etiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3557069\">",
"    <span class=\"h2\">",
"     Chronic fatigue syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are conflicting data as to whether there is [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10265/abstract/40,41\">",
"     40,41",
"    </a>",
"    ] or is not [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10265/abstract/42,43\">",
"     42,43",
"    </a>",
"    ] an association between chronic fatigue syndrome and increasing HHV-6 antibody titers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/6/30825?source=see_link\">",
"     \"Clinical features and diagnosis of chronic fatigue syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3557076\">",
"    <span class=\"h2\">",
"     Neoplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;HHV-6 antigens and DNA have been detected in a number of types of malignant tissue, including those from non-Hodgkin lymphomas, Hodgkin lymphoma, oral carcinomas, glioma, and others [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10265/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. Although isolated studies have suggested an association between HHV-6 and certain malignancies, these have not been subsequently confirmed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3557083\">",
"    <span class=\"h2\">",
"     Myocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some studies have suggested that HHV-6 may also be implicated in the pathogenesis of myocarditis with subsequent cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10265/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22986?source=see_link\">",
"     \"Etiology and pathogenesis of myocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2140351578\">",
"    <span class=\"h2\">",
"     Cutaneous drug reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug-induced hypersensitivity syndrome (DIHS) has been associated with reactivation of HHV-6 as well as Epstein-Barr virus and cytomegalovirus [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10265/abstract/48-52\">",
"     48-52",
"    </a>",
"    ], although a causal link between these viruses and DIHS has not been demonstrated. One hypothesis is that the rash could be mediated by increased activated CD8+ T lymphocytes directed against these viruses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Lack of interaction with HIV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although in vitro studies have suggested synergistic interactions between HIV-1 and HHV-6, clinical interactions between the viruses have not been demonstrated, as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although HHV-6 and HIV are both tropic for CD4+ T-cells, there is no evidence that HHV-6 influences the course of HIV-1 disease progression [",
"      <a class=\"abstract\" href=\"UTD.htm?10/1/10265/abstract/53,54\">",
"       53,54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A study evaluating HHV-6 DNA in the CSF of HIV-infected subjects failed to show any causal relationship between the presence of HHV-6 and neurologic disease [",
"      <a class=\"abstract\" href=\"UTD.htm?10/1/10265/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      HHV-6 probably has no direct role in the pathogenesis of HIV-associated B cell lymphoma or Hodgkin lymphoma [",
"      <a class=\"abstract\" href=\"UTD.htm?10/1/10265/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Studies looking at HHV-6 in the lungs of HIV-1 infected subjects with pulmonary symptoms failed to demonstrate any association [",
"      <a class=\"abstract\" href=\"UTD.htm?10/1/10265/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since HHV-6 infection is common in childhood, most adults demonstrate antibodies to the virus. Most illnesses in adults are due to immunosuppression and reactivation of latent infection.",
"   </p>",
"   <p>",
"    The diagnosis of acute clinical syndromes, like encephalitis or pneumonitis, requires isolation of HHV-6 or detection of HHV-6 DNA in clinical specimens such as cerebrospinal fluid, respiratory secretions, or brain or lung tissue. In suspected HHV-6 encephalitis, brain MRI imaging may be normal or demonstrate focal findings, such as enhancement in the temporal lobes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10265/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Serodiagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of tests are available for the detection of HHV-6 IgG antibody responses. These include indirect immunofluorescence assays, anti-complement immunofluorescence, competitive radioimmunoassay, neutralization and enzyme immunoassays [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10265/abstract/57-59\">",
"     57-59",
"    </a>",
"    ]. The sensitivity of these assays varies. They do not distinguish between the HHV-6 A and B variants and there is cross-reactivity with HHV-7.",
"   </p>",
"   <p>",
"    Because most people over two years of age are seropositive for HHV-6, a single positive result cannot be interpreted. Paired sera need to be collected, with a &ge;4-fold rise in titers considered diagnostic. Seroconversion from negative to positive is good evidence of primary infection.",
"   </p>",
"   <p>",
"    HHV-6 IgM develops within four to seven days of infection. However, approximately five percent of healthy adults are IgM-positive at any given time, making this test unreliable for a definitive diagnosis. The mu-capture immunoassay appears to perform more accurately than older generation assays and does not cross react with Epstein-Barr virus or cytomegalovirus IgM positive sera [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10265/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Virus detection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testing of tissue for virus is feasible with monoclonal antibodies against specific HHV-6A and B antigens as well as a polyclonal antibody against HHV-6 U90 protein [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10265/abstract/61\">",
"     61",
"    </a>",
"    ]. Qualitative DNA PCR assays are also available and can detect HHV-6 from several tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10265/abstract/5,62-65\">",
"     5,62-65",
"    </a>",
"    ]. However, because HHV-6 causes latent infection, the clinical significance of this finding needs to be better defined. Quantitation of cell-free virus in serum, plasma, and CSF by real-time PCR is used to diagnose active HHV-6 infections [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10265/abstract/66-70\">",
"     66-70",
"    </a>",
"    ]. One study has shown that reverse-transcriptase PCR performed using peripheral blood mononuclear cells may be more specific for detecting active infection compared with qualitative PCR or real-time PCR [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10265/abstract/71\">",
"     71",
"    </a>",
"    ]. The diagnosis of HHV-6 encephalitis in hematopoietic cell transplant recipients is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/40/30346?source=see_link&amp;anchor=H665911236#H665911236\">",
"     \"Human herpesvirus 6 infection in hematopoietic cell transplant recipients\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinicians need to be aware that aside from latent infection in peripheral blood mononuclear cells, HHV-6 can also be integrated into chromosomes, which may lead to inaccuracies in HHV-6 diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/40/30346?source=see_link&amp;anchor=H358775122#H358775122\">",
"     \"Human herpesvirus 6 infection in hematopoietic cell transplant recipients\", section on 'Detecting chromosomal integration'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     TREATMENT AND PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;HHV-6 infections in immunocompetent patients are generally not treated since most cases are self-limited and antiviral therapy has not been studied in such patients. In severe cases of HHV-6 encephalitis in immunocompetent children,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    therapy has been used, although there was no evidence of benefit in a small case series [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10265/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Certain HHV-6 infections in immunocompromised hosts (eg, encephalitis in hematopoietic stem cell transplant recipients) are often treated with antiviral agents given the high morbidity of such infections, although efficacy data are limited and no controlled trials have been reported.",
"   </p>",
"   <p>",
"    In vitro, HHV-6 has a susceptibility pattern similar to cytomegalovirus (CMV).",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"     Foscarnet",
"    </a>",
"    is active against both HHV-6A and -B, whereas",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    is active against HHV-6B but, in some reports, HHV-6A was relatively resistant [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10265/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. Mutations in the polymerase gene U69 at codon M318V and in the gene U38 (P462S and A565V) are associated with a ganciclovir resistant phenotype and with treatment failure [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10265/abstract/75,76\">",
"     75,76",
"    </a>",
"    ]. Cidofovir-resistant mutants have also been selected in vitro, resulting in the R798I mutation, which confers a 200-fold increase in IC",
"    <sub>",
"     50",
"    </sub>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10265/abstract/77\">",
"     77",
"    </a>",
"    ]. One study in hematopoietic stem cell transplant recipients suggested that ganciclovir modestly reduced HHV-6 in saliva compared to no therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10265/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although these studies suggest that certain antivirals may have some effect on HHV-6 replication, there are no controlled clinical trials to show benefits in humans. Several anecdotal case reports and case series have suggested improvement in presumed HHV-6 encephalitis after administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10265/abstract/7,22,79-83\">",
"     7,22,79-83",
"    </a>",
"    ]. However, these findings require confirmation in carefully controlled trials. The treatment of HHV-6 encephalitis in HCT recipients is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/40/30346?source=see_link&amp;anchor=H665911113#H665911113\">",
"     \"Human herpesvirus 6 infection in hematopoietic cell transplant recipients\", section on 'Antiviral therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3555957\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Human herpesvirus 6 (HHV-6) was first isolated and characterized from patients with lymphoproliferative disorders and was originally named human B-lymphotropic virus. Its name was changed to human herpesvirus 6 as its tropism was further characterized. Like most herpesviruses, HHV-6 may remain latent in certain host cells after primary infection, but can be reactivated in immunocompromised patients. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HHV-6 infections usually occur during childhood and result in generally mild, self-limited illnesses. Primary infection in adults is rare. However, a mononucleosis-like syndrome of varying severity with prolonged lymphadenopathy has been described in association with HHV-6 seroconversion in adults. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Immunocompetent hosts'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Encephalitis of variable severity has been associated rarely with HHV-6 infection in immunocompetent patients. Clinical presentations have included altered level of consciousness, seizures, psychosis, acute cerebellar ataxia, and focal neurological signs (eg, cranial nerve deficits or hemiparesis). Neurologic outcomes have varied from full recovery to death. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Encephalitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HHV-6 has been associated with mesial temporal lobe epilepsy (MTLE). HHV-6 DNA was recovered from brain biopsies from patients with MTLE more frequently than in controls, suggesting a pathogenic effect of the virus. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Mesial temporal lobe epilepsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immunosuppression secondary to solid organ or hematopoietic cell transplantation (HCT) favors reactivation and replication of HHV-6, and may result in viremia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      clinical illness. Clinical syndromes associated with HHV-6 in transplant recipients include pneumonitis, hepatitis, encephalitis, and bone marrow suppression. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Transplant recipients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Associations between HHV-6 and several diseases have been proposed, but not proven. These include multiple sclerosis, hepatic failure, chronic fatigue syndrome, neoplasia, and myocarditis. (See",
"      <a class=\"local\" href=\"#H3557047\">",
"       'Unproven associations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Since HHV-6 infection is common in childhood, most adults demonstrate antibodies to the virus. Most illnesses in adults result from immunosuppression and reactivation of latent infection. The diagnosis of acute HHV-6 clinical syndromes, like encephalitis or pneumonitis, requires isolation of the virus or detection of HHV-6 DNA in clinical specimens such as cerebrospinal fluid, respiratory secretions, or brain or lung tissue. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HHV-6 infections in immunocompetent patients are generally not treated since most cases are self-limited and antiviral therapy has not been carefully studied in such patients. In severe cases of HHV-6 encephalitis in immunocompetent children,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"       ganciclovir",
"      </a>",
"      therapy has been used although there was no evidence of benefit in a small case series. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Treatment and prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Certain HHV-6 infections in immunocompromised hosts (eg, encephalitis in HCT recipients) are often treated with antiviral agents, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"       foscarnet",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"       ganciclovir",
"      </a>",
"      , given the high morbidity of such infections, although efficacy data are limited and no controlled trials have been reported. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Treatment and prevention'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/40/30346?source=see_link&amp;anchor=H665911113#H665911113\">",
"       \"Human herpesvirus 6 infection in hematopoietic cell transplant recipients\", section on 'Antiviral therapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/1\">",
"      Salahuddin SZ, Ablashi DV, Markham PD, et al. Isolation of a new virus, HBLV, in patients with lymphoproliferative disorders. Science 1986; 234:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/2\">",
"      Ablashi DV, Salahuddin SZ, Josephs SF, et al. HBLV (or HHV-6) in human cell lines. Nature 1987; 329:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/3\">",
"      Akashi K, Eizuru Y, Sumiyoshi Y, et al. Brief report: severe infectious mononucleosis-like syndrome and primary human herpesvirus 6 infection in an adult. N Engl J Med 1993; 329:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/4\">",
"      Niederman JC, Liu CR, Kaplan MH, Brown NA. Clinical and serological features of human herpesvirus-6 infection in three adults. Lancet 1988; 2:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/5\">",
"      Maric I, Bryant R, Abu-Asab M, et al. Human herpesvirus-6-associated acute lymphadenitis in immunocompetent adults. Mod Pathol 2004; 17:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/6\">",
"      McCullers JA, Lakeman FD, Whitley RJ. Human herpesvirus 6 is associated with focal encephalitis. Clin Infect Dis 1995; 21:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/7\">",
"      Birnbaum T, Padovan CS, Sporer B, et al. Severe meningoencephalitis caused by human herpesvirus 6 type B in an immunocompetent woman treated with ganciclovir. Clin Infect Dis 2005; 40:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/8\">",
"      Isaacson E, Glaser CA, Forghani B, et al. Evidence of human herpesvirus 6 infection in 4 immunocompetent patients with encephalitis. Clin Infect Dis 2005; 40:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/9\">",
"      Yao K, Honarmand S, Espinosa A, et al. Detection of human herpesvirus-6 in cerebrospinal fluid of patients with encephalitis. Ann Neurol 2009; 65:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/10\">",
"      Hata A, Fujita M, Morishima T, et al. Acute cerebellar ataxia associated with primary human herpesvirus-6 infection: a report of two cases. J Paediatr Child Health 2008; 44:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/11\">",
"      Troy SB, Blackburn BG, Yeom K, et al. Severe encephalomyelitis in an immunocompetent adult with chromosomally integrated human herpesvirus 6 and clinical response to treatment with foscarnet plus ganciclovir. Clin Infect Dis 2008; 47:e93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/12\">",
"      Whitley RJ, Lakeman FD. Human herpesvirus 6 infection of the central nervous system: is it just a case of mistaken association? Clin Infect Dis 2005; 40:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/13\">",
"      Donati D, Akhyani N, Fogdell-Hahn A, et al. Detection of human herpesvirus-6 in mesial temporal lobe epilepsy surgical brain resections. Neurology 2003; 61:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/14\">",
"      Fotheringham J, Donati D, Akhyani N, et al. Association of human herpesvirus-6B with mesial temporal lobe epilepsy. PLoS Med 2007; 4:e180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/15\">",
"      Gewurz BE, Marty FM, Baden LR, Katz JT. Human herpesvirus 6 encephalitis. Curr Infect Dis Rep 2008; 10:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/16\">",
"      Dockrell DH, Paya CV. Human herpesvirus-6 and -7 in transplantation. Rev Med Virol 2001; 11:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/17\">",
"      Hentrich M, Oruzio D, J&auml;ger G, et al. Impact of human herpesvirus-6 after haematopoietic stem cell transplantation. Br J Haematol 2005; 128:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/18\">",
"      Yoshikawa T, Suga S, Asano Y, et al. A prospective study of human herpesvirus-6 infection in renal transplantation. Transplantation 1992; 54:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/19\">",
"      Humar A, Malkan G, Moussa G, et al. Human herpesvirus-6 is associated with cytomegalovirus reactivation in liver transplant recipients. J Infect Dis 2000; 181:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/20\">",
"      Potenza L, Luppi M, Barozzi P, et al. HHV-6A in syncytial giant-cell hepatitis. N Engl J Med 2008; 359:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/21\">",
"      Halme L, Arola J, H&ouml;ckerstedt K, Lautenschlager I. Human herpesvirus 6 infection of the gastroduodenal mucosa. Clin Infect Dis 2008; 46:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/22\">",
"      Nash PJ, Avery RK, Tang WH, et al. Encephalitis owing to human herpesvirus-6 after cardiac transplant. Am J Transplant 2004; 4:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/23\">",
"      Cone RW, Hackman RC, Huang ML, et al. Human herpesvirus 6 in lung tissue from patients with pneumonitis after bone marrow transplantation. N Engl J Med 1993; 329:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/24\">",
"      Carrigan DR, Drobyski WR, Russler SK, et al. Interstitial pneumonitis associated with human herpesvirus-6 infection after marrow transplantation. Lancet 1991; 338:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/25\">",
"      Cone RW, Huang ML, Hackman RC. Human herpesvirus 6 and pneumonia. Leuk Lymphoma 1994; 15:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/26\">",
"      Merlino C, Giacchino F, Segoloni GP, Ponzi AN. Human herpesvirus-6 infection and renal transplantation. Transplantation 1992; 53:1382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/27\">",
"      Volin L, Lautenschlager I, Juvonen E, et al. Human herpesvirus 6 antigenaemia in allogeneic stem cell transplant recipients: impact on clinical course and association with other beta-herpesviruses. Br J Haematol 2004; 126:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/28\">",
"      Dietrich J, Blumberg BM, Roshal M, et al. Infection with an endemic human herpesvirus disrupts critical glial precursor cell properties. J Neurosci 2004; 24:4875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/29\">",
"      Challoner PB, Smith KT, Parker JD, et al. Plaque-associated expression of human herpesvirus 6 in multiple sclerosis. Proc Natl Acad Sci U S A 1995; 92:7440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/30\">",
"      Rotola A, Merlotti I, Caniatti L, et al. Human herpesvirus 6 infects the central nervous system of multiple sclerosis patients in the early stages of the disease. Mult Scler 2004; 10:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/31\">",
"      Soldan SS, Leist TP, Juhng KN, et al. Increased lymphoproliferative response to human herpesvirus type 6A variant in multiple sclerosis patients. Ann Neurol 2000; 47:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/32\">",
"      Alvarez-Lafuente R, De las Heras V, Bartolom&eacute; M, et al. Relapsing-remitting multiple sclerosis and human herpesvirus 6 active infection. Arch Neurol 2004; 61:1523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/33\">",
"      Alvarez-Lafuente R, De Las Heras V, Bartolom&eacute; M, et al. Beta-interferon treatment reduces human herpesvirus-6 viral load in multiple sclerosis relapses but not in remission. Eur Neurol 2004; 52:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/34\">",
"      Alvarez-Lafuente R, de las Heras V, Garc&iacute;a-Montojo M, et al. Human herpesvirus-6 and multiple sclerosis: relapsing-remitting versus secondary progressive. Mult Scler 2007; 13:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/35\">",
"      Tuke PW, Hawke S, Griffiths PD, Clark DA. Distribution and quantification of human herpesvirus 6 in multiple sclerosis and control brains. Mult Scler 2004; 10:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/36\">",
"      Rotola A, Cassai E, Tola MR, et al. Human herpesvirus 6 is latent in peripheral blood of patients with relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 1999; 67:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/37\">",
"      Hay KA, Tenser RB. Leukotropic herpesviruses in multiple sclerosis. Mult Scler 2000; 6:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/38\">",
"      H&auml;rm&auml; M, H&ouml;ckerstedt K, Lautenschlager I. Human herpesvirus-6 and acute liver failure. Transplantation 2003; 76:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/39\">",
"      Chevret L, Boutolleau D, Halimi-Idri N, et al. Human herpesvirus-6 infection: a prospective study evaluating HHV-6 DNA levels in liver from children with acute liver failure. J Med Virol 2008; 80:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/40\">",
"      Sairenji T, Yamanishi K, Tachibana Y, et al. Antibody responses to Epstein-Barr virus, human herpesvirus 6 and human herpesvirus 7 in patients with chronic fatigue syndrome. Intervirology 1995; 38:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/41\">",
"      Ablashi DV, Eastman HB, Owen CB, et al. Frequent HHV-6 reactivation in multiple sclerosis (MS) and chronic fatigue syndrome (CFS) patients. J Clin Virol 2000; 16:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/42\">",
"      Gold D, Bowden R, Sixbey J, et al. Chronic fatigue. A prospective clinical and virologic study. JAMA 1990; 264:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/43\">",
"      Levine PH, Jacobson S, Pocinki AG, et al. Clinical, epidemiologic, and virologic studies in four clusters of the chronic fatigue syndrome. Arch Intern Med 1992; 152:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/44\">",
"      Di Luca D, Dolcetti R, Mirandola P, et al. Human herpesvirus 6: a survey of presence and variant distribution in normal peripheral lymphocytes and lymphoproliferative disorders. J Infect Dis 1994; 170:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/45\">",
"      Yadav M, Chandrashekran A, Vasudevan DM, Ablashi DV. Frequent detection of human herpesvirus 6 in oral carcinoma. J Natl Cancer Inst 1994; 86:1792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/46\">",
"      Chi J, Gu B, Zhang C, et al. Human herpesvirus 6 latent infection in patients with glioma. J Infect Dis 2012; 206:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/47\">",
"      Comar M, D'Agaro P, Campello C, et al. Human herpes virus 6 in archival cardiac tissues from children with idiopathic dilated cardiomyopathy or congenital heart disease. J Clin Pathol 2009; 62:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/48\">",
"      Picard D, Janela B, Descamps V, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response. Sci Transl Med 2010; 2:46ra62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/49\">",
"      Ozcan D, Se&ccedil;kin D, Bilezik&ccedil;i B, Arslan H. The role of human herpesvirus-6, Epstein&ndash;Barr virus and cytomegalovirus infections in the etiopathogenesis of different types of cutaneous drug reactions. Int J Dermatol 2010; 49:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/50\">",
"      Goto M, Shimizu F, Takeo N, et al. Drug-induced hypersensitivity syndrome due to carbapenem antibiotics. J Dermatol 2010; 37:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/51\">",
"      Gentile I, Talamo M, Borgia G. Is the drug-induced hypersensitivity syndrome (DIHS) due to human herpesvirus 6 infection or to allergy-mediated viral reactivation? Report of a case and literature review. BMC Infect Dis 2010; 10:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/52\">",
"      Saida S, Yoshida A, Tanaka R, et al. A case of drug-induced hypersensitivity syndrome-like symptoms following HHV-6 encephalopathy. Allergol Int 2010; 59:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/53\">",
"      Spira TJ, Bozeman LH, Sanderlin KC, et al. Lack of correlation between human herpesvirus-6 infection and the course of human immunodeficiency virus infection. J Infect Dis 1990; 161:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/54\">",
"      Fairfax MR, Schacker T, Cone RW, et al. Human herpesvirus 6 DNA in blood cells of human immunodeficiency virus-infected men: correlation of high levels with high CD4 cell counts. J Infect Dis 1994; 169:1342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/55\">",
"      Bossolasco S, Marenzi R, Dahl H, et al. Human herpesvirus 6 in cerebrospinal fluid of patients infected with HIV: frequency and clinical significance. J Neurol Neurosurg Psychiatry 1999; 67:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/56\">",
"      Dolcetti R, Di Luca D, Carbone A, et al. Human herpesvirus 6 in human immunodeficiency virus-infected individuals: association with early histologic phases of lymphadenopathy syndrome but not with malignant lymphoproliferative disorders. J Med Virol 1996; 48:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/57\">",
"      Couillard M, Joly JR, Desch&ecirc;nes L, Richer G. Evaluation of variables in immunofluorescence procedures for the detection of antibodies against human herpesvirus 6 (HHV-6). Diagn Microbiol Infect Dis 1992; 15:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/58\">",
"      Robert C, Agut H, Aubin JT, et al. Detection of antibodies to human herpesvirus-6 using immunofluorescence assay. Res Virol 1990; 141:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/59\">",
"      Chou SW, Scott KM. Rises in antibody to human herpesvirus 6 detected by enzyme immunoassay in transplant recipients with primary cytomegalovirus infection. J Clin Microbiol 1990; 28:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/60\">",
"      Nielsen L, Vestergaard BF. A mu-capture immunoassay for detection of human herpes virus-6 (HHV-6) IgM antibodies in human serum. J Clin Virol 2002; 25:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/61\">",
"      Nishimura N, Yoshikawa T, Ozaki T, et al. In vitro and in vivo analysis of human herpesvirus-6 U90 protein expression. J Med Virol 2005; 75:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/62\">",
"      Norton RA, Caserta MT, Hall CB, et al. Detection of human herpesvirus 6 by reverse transcription-PCR. J Clin Microbiol 1999; 37:3672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/63\">",
"      Fujiwara N, Namba H, Ohuchi R, et al. Monitoring of human herpesvirus-6 and -7 genomes in saliva samples of healthy adults by competitive quantitative PCR. J Med Virol 2000; 61:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/64\">",
"      Blumberg BM, Mock DJ, Powers JM, et al. The HHV6 paradox: ubiquitous commensal or insidious pathogen? A two-step in situ PCR approach. J Clin Virol 2000; 16:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/65\">",
"      Ihira M, Ohta A, Sugata K, et al. Loop-mediated isothermal amplification for discriminating between human herpesvirus 6 A and B. J Virol Methods 2008; 154:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/66\">",
"      Fotheringham J, Akhyani N, Vortmeyer A, et al. Detection of active human herpesvirus-6 infection in the brain: correlation with polymerase chain reaction detection in cerebrospinal fluid. J Infect Dis 2007; 195:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/67\">",
"      Canto CL, Sumita LM, Machado AF, et al. Optimization of the Sybr Green real time PCR for the detection of Human Herpes Virus type 6 (HHV-6). Rev Inst Med Trop Sao Paulo 2008; 50:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/68\">",
"      Deback C, Agbalika F, Scieux C, et al. Detection of human herpesviruses HHV-6, HHV-7 and HHV-8 in whole blood by real-time PCR using the new CMV, HHV-6, 7, 8 R-gene kit. J Virol Methods 2008; 149:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/69\">",
"      Engelmann I, Petzold DR, Kosinska A, et al. Rapid quantitative PCR assays for the simultaneous detection of herpes simplex virus, varicella zoster virus, cytomegalovirus, Epstein-Barr virus, and human herpesvirus 6 DNA in blood and other clinical specimens. J Med Virol 2008; 80:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/70\">",
"      Flamand L, Gravel A, Boutolleau D, et al. Multicenter comparison of PCR assays for detection of human herpesvirus 6 DNA in serum. J Clin Microbiol 2008; 46:2700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/71\">",
"      Caserta MT, Hall CB, Schnabel K, et al. Diagnostic assays for active infection with human herpesvirus 6 (HHV-6). J Clin Virol 2010; 48:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/72\">",
"      Crawford JR, Kadom N, Santi MR, et al. Human herpesvirus 6 rhombencephalitis in immunocompetent children. J Child Neurol 2007; 22:1260.",
"     </a>",
"    </li>",
"    <li>",
"     Williams MV. HHV-6: response to antiviral agents. In: Human herpesvirus-6: epidemiology, molecular biology, and clinical pathology, Ablashi DV, Krueger RF, Salahuddin SZ (Eds), Elsevier Biomedical Press, Amsterdam  p.317.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/74\">",
"      Manichanh C, Olivier-Aubron C, Lagarde JP, et al. Selection of the same mutation in the U69 protein kinase gene of human herpesvirus-6 after prolonged exposure to ganciclovir in vitro and in vivo. J Gen Virol 2001; 82:2767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/75\">",
"      De Bolle L, Manichanh C, Agut H, et al. Human herpesvirus 6 DNA polymerase: enzymatic parameters, sensitivity to ganciclovir and determination of the role of the A961V mutation in HHV-6 ganciclovir resistance. Antiviral Res 2004; 64:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/76\">",
"      Isegawa Y, Hara J, Amo K, et al. Human herpesvirus 6 ganciclovir-resistant strain with amino acid substitutions associated with the death of an allogeneic stem cell transplant recipient. J Clin Virol 2009; 44:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/77\">",
"      Bonnafous P, Boutolleau D, Naesens L, et al. Characterization of a cidofovir-resistant HHV-6 mutant obtained by in vitro selection. Antiviral Res 2008; 77:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/78\">",
"      Ljungman P, Dahl H, Xu YH, et al. Effectiveness of ganciclovir against human herpesvirus-6 excreted in saliva in stem cell transplant recipients. Bone Marrow Transplant 2007; 39:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/79\">",
"      Ogata M, Kikuchi H, Satou T, et al. Human herpesvirus 6 DNA in plasma after allogeneic stem cell transplantation: incidence and clinical significance. J Infect Dis 2006; 193:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/80\">",
"      Tiacci E, Luppi M, Barozzi P, et al. Fatal herpesvirus-6 encephalitis in a recipient of a T-cell-depleted peripheral blood stem cell transplant from a 3-loci mismatched related donor. Haematologica 2000; 85:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/81\">",
"      Seeley WW, Marty FM, Holmes TM, et al. Post-transplant acute limbic encephalitis: clinical features and relationship to HHV6. Neurology 2007; 69:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/82\">",
"      Bethge W, Beck R, Jahn G, et al. Successful treatment of human herpesvirus-6 encephalitis after bone marrow transplantation. Bone Marrow Transplant 1999; 24:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10265/abstract/83\">",
"      Olli-L&auml;hdesm&auml;ki T, Haataja L, Parkkola R, et al. High-dose ganciclovir in HHV-6 encephalitis of an immunocompetent child. Pediatr Neurol 2010; 43:53.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8320 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-48A44A7773-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_1_10265=[""].join("\n");
var outline_f10_1_10265=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3555957\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3555976\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Immunocompetent hosts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      - Primary infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Encephalitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Mesial temporal lobe epilepsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Viremia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Encephalitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Pneumonitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Possible association with graft rejection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Solid organ transplant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Hematopoietic cell transplant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3557047\">",
"      UNPROVEN ASSOCIATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3557055\">",
"      Multiple sclerosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3557062\">",
"      Fulminant hepatic failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3557069\">",
"      Chronic fatigue syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3557076\">",
"      Neoplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3557083\">",
"      Myocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2140351578\">",
"      Cutaneous drug reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Lack of interaction with HIV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Serodiagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Virus detection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      TREATMENT AND PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3555957\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/17/2330?source=related_link\">",
"      Acute liver failure in adults: Etiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/6/30825?source=related_link\">",
"      Clinical features and diagnosis of chronic fatigue syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32458?source=related_link\">",
"      Epidemiology and clinical features of multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22986?source=related_link\">",
"      Etiology and pathogenesis of myocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31577?source=related_link\">",
"      Human herpesvirus 6 infection in children: Clinical manifestations; diagnosis; and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/40/30346?source=related_link\">",
"      Human herpesvirus 6 infection in hematopoietic cell transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29433?source=related_link\">",
"      Infection in the solid organ transplant recipient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/14/40167?source=related_link\">",
"      Virology, pathogenesis, and epidemiology of human herpesvirus 6 infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_1_10266="Overview of pediatric non-Hodgkin lymphoma";
var content_f10_1_10266=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of pediatric non-Hodgkin lymphoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/1/10266/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/1/10266/contributors\">",
"     Amanda M Termuhlen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/1/10266/contributors\">",
"     Thomas G Gross, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/1/10266/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/1/10266/contributors\">",
"     Julie R Park, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/1/10266/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/1/10266/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/1/10266/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 26, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1876613\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-Hodgkin lymphoma (NHL) consists of a diverse group of malignant neoplasms of the lymphoid tissues variously derived from B cell progenitors, T cell progenitors, mature B cells, or mature T cells. Unlike in adults where low-grade, clinically indolent NHL subtypes predominate, most pediatric NHL cases are of high grade and have an aggressive clinical behavior [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10266/abstract/1\">",
"     1",
"    </a>",
"    ]. Whenever possible, children with NHL should be treated in a comprehensive pediatric oncology center by a multidisciplinary team experienced in the diagnosis and care of children with cancer.",
"   </p>",
"   <p>",
"    This topic will provide an overview of NHL in children and adolescents, focusing on issues that are of interest to primary care providers. The pathobiology of NHL and its diagnosis and management in adults are presented separately, as is an overview of Hodgkin lymphoma in children and adolescents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21337?source=see_link\">",
"     \"Classification of the hematopoietic neoplasms\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=see_link\">",
"     \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/6/32874?source=see_link\">",
"     \"Overview of Hodgkin lymphoma in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1876620\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;NHL is the fifth most common diagnosis of pediatric cancer in children under the age of 15 years, and it accounts for approximately 7 percent of childhood cancers in the developed world [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10266/abstract/2\">",
"     2",
"    </a>",
"    ]. In the United States, approximately 800 new cases of pediatric NHL are diagnosed annually with an incidence of 10 to 20 cases per million people per year [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10266/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. This incidence appears to be increasing overall, largely thought to reflect a rise in NHL among adolescents. The median age at diagnosis is approximately 10 years, and the incidence increases with age [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10266/abstract/2\">",
"     2",
"    </a>",
"    ]. Lymphomas are rare in infants (&le;1 percent) and account for approximately 4, 14, 22, and 25 percent of neoplasms in children age 1 to 4, 5 to 9, 10 to 14, and 15 to 19 years, respectively. There is a male predominance, and whites are more commonly affected than African Americans.",
"   </p>",
"   <p>",
"    The incidence and distribution of specific NHL subtypes differs by population (eg, age, race) and geographical region. In general, the most common subtypes of pediatric NHL are derived from B cell progenitors. In the United States and other developed countries, the most common subtypes are Burkitt lymphoma, diffuse large B cell lymphoma, lymphoblastic T cell or B cell lymphoma, and anaplastic large cell lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10266/abstract/6\">",
"     6",
"    </a>",
"    ]. Other subtypes (eg, follicular lymphoma, marginal zone lymphoma) are less common, accounting for approximately 7 percent of pediatric NHL.",
"   </p>",
"   <p>",
"    Both congenital and acquired immunodeficiency syndromes are associated with an increased risk of NHL. Congenital immunodeficiencies associated with NHL include common variable immunodeficiency, Wiskott-Aldrich syndrome, ataxia telangiectasia, and X-linked lymphoproliferative syndrome. Congenital immunodeficiencies may impact treatment decisions. As an example, the use of diagnostic tests and therapy involving x-rays and ionizing radiation should be limited in children with ataxia telangiectasia to minimize the risk of somatic mutations and subsequent malignancy. Acquired immunodeficiencies include HIV and the use of immunosuppressive medications. Post-transplant lymphoproliferative disorders can follow solid organ and hematopoietic cell transplantation. (See",
"    <a class=\"local\" href=\"#H1883012\">",
"     'Lymphoproliferative disease in the immune compromised patient'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/63/31738?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of post-transplant lymphoproliferative disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/63/31738?source=see_link&amp;anchor=H16929521#H16929521\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of post-transplant lymphoproliferative disorders\", section on 'Epidemiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/60/23497?source=see_link\">",
"     \"Ataxia-telangiectasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1876627\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1468535\">",
"    <span class=\"h2\">",
"     Oncologic emergencies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potentially emergent complications of NHL may be present at the time of diagnosis and need to be considered during the initial workup and evaluation of a patient with suspected pediatric NHL. Prompt recognition and therapy are critical for these situations, which may be life-threatening or may interfere with and delay treatment of the underlying NHL. These emergencies are described in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41129?source=see_link\">",
"     \"Emergencies in pediatric cancer patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These can include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Superior or inferior vena cava obstruction",
"     </li>",
"     <li>",
"      Acute airway obstruction",
"     </li>",
"     <li>",
"      Intestinal obstruction, intussusception",
"     </li>",
"     <li>",
"      Spinal cord compression",
"     </li>",
"     <li>",
"      Pericardial tamponade",
"     </li>",
"     <li>",
"      Lymphomatous meningitis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      CNS mass lesions",
"     </li>",
"     <li>",
"      Hyperuricemia and tumor lysis syndrome",
"     </li>",
"     <li>",
"      Ureteral obstruction, unilateral or bilateral hydronephrosis",
"     </li>",
"     <li>",
"      Venous thromboembolic disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with large mediastinal masses are at increased risk of respiratory or cardiac arrest during general anesthesia or heavy sedation. Patients who present with cardiorespiratory symptoms or radiographic evidence of tracheal obstruction are at greatest risk of perioperative respiratory morbidity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/24/31111?source=see_link&amp;anchor=H14#H14\">",
"     \"Evaluation of mediastinal masses\", section on 'Management considerations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Tumor lysis syndrome is an oncologic emergency that is caused by massive tumor cell lysis and the release of large amounts of potassium, phosphate, and uric acid into the systemic circulation. Deposition of uric acid",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    calcium phosphate crystals in the renal tubules can result in acute renal failure, which is usually anuric. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=see_link\">",
"     \"Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3402?source=see_link\">",
"     \"Tumor lysis syndrome: Prevention and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1876635\">",
"    <span class=\"h2\">",
"     Signs and symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of pediatric NHL varies depending upon the type of lymphoma and the areas of involvement. Symptoms develop quickly, usually over one to three weeks. NHL commonly presents as enlarging, non-tender lymphadenopathy or as symptoms due to the compression of surrounding structures, such as new onset wheezing, facial swelling, respiratory distress, asymmetrical tonsils, or acute abdominal pain. Hepatic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    splenic enlargement may be present in patients with advanced stage NHL.",
"   </p>",
"   <p>",
"    Central nervous system (CNS) involvement occurs in 6 percent of pediatric NHL with rates ranging from 8.8 percent in Burkitt lymphoma to &lt;3 percent in diffuse large B cell lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10266/abstract/7\">",
"     7",
"    </a>",
"    ]. A significant minority of patients will have systemic complaints of fever, weight loss, or night sweats (ie, B symptoms). While certain clinical presentations are suggestive of specific NHL histologies, a definitive diagnosis requires a biopsy of involved tissue, as described below. (See",
"    <a class=\"local\" href=\"#H1876663\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1876642\">",
"    <span class=\"h2\">",
"     Laboratory features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory tests that may be abnormal in patients with newly diagnosed pediatric NHL are listed below. It is important to remember that the complete blood count (CBC) may be normal.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Unexplained anemia, thrombocytopenia, or leukopenia &mdash; These changes in peripheral blood counts can be due to extensive bone marrow infiltration, hypersplenism from splenic involvement, or blood loss from gastrointestinal tract involvement. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23914?source=see_link\">",
"       \"Hematologic consequences of malignancy: Anemia and bleeding\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=see_link\">",
"       \"Anemia of chronic disease (anemia of chronic inflammation)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hyperuricemia &mdash; Patients with rapidly proliferating tumors, particularly Burkitt lymphoma or lymphoblastic lymphoma, may demonstrate manifestations of tumor lysis syndrome with elevated uric acid, potassium, and diminished renal function. Hyperuricemia and tumor lysis syndrome are more commonly seen in patients presenting with underlying renal failure, due to either renal infiltration with lymphoma, pre-existing renal disease, or coincident obstruction of the ureters secondary to NHL. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/24/1416?source=see_link\">",
"       \"Asymptomatic hyperuricemia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27541?source=see_link\">",
"       \"Uric acid renal diseases\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=see_link\">",
"       \"Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Elevated level of serum lactate dehydrogenase (LDH) &mdash; LDH elevation associated with NHL may be due to high tumor burden, extensive infiltration of the liver, or association with particular rapidly proliferative NHL such as Burkitt or lymphoblastic lymphoma. An elevated LDH, especially if greater than two to three times normal, is associated with a poorer prognosis [",
"      <a class=\"abstract\" href=\"UTD.htm?10/1/10266/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1876649\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial imaging studies (eg, ultrasound, radiographs, computed tomography) are often performed as part of the evaluation of presenting symptoms (eg, abdominal pain). These may demonstrate masses",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lymphadenopathy in the neck, chest, or abdomen. Pediatric NHL, unlike Hodgkin lymphoma, may involve non-contiguous areas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=see_link&amp;anchor=H13#H13\">",
"     \"Initial evaluation and staging of non-Hodgkin lymphoma\", section on 'Routine imaging studies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, routine staging of pediatric NHL should include contrast enhanced computerized tomographic (CT) imaging of the neck, chest, abdomen, and pelvis. This CT both serves to help determine disease stage at diagnosis and to provide a baseline study for comparison to determine response to treatment. Integrated positron emissions tomography",
"    <span class=\"nowrap\">",
"     (PET)/CT",
"    </span>",
"    scanning is more sensitive and specific than CT in certain histologic subtypes of NHL, including the most common subtypes seen in children [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10266/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1876670\">",
"     'Staging'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Imaging of the bones with plain films, CT,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    magnetic resonance imaging (MRI) is not routinely performed in NHL, but is indicated in the presence of bone pain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    suspicion of a pathologic fracture. Bone lesions in NHL are mostly osteolytic on plain films, in contrast to those in patients with Hodgkin lymphoma, which are predominantly osteoblastic. If there is suspicion of spinal cord compression, urgent MRI of the entire spinal column is indicated, since multiple sites may be involved. MRI (with and without gadolinium) of the head is also indicated for patients with neurologic symptoms or signs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/17/39194?source=see_link\">",
"     \"Secondary involvement of the central nervous system by non-Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1876663\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of NHL is based upon the pathologic evaluation of involved tissue, usually an abdominal mass, extranodal site, or lymph node, interpreted within the clinical context [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10266/abstract/10\">",
"     10",
"    </a>",
"    ]. Subtypes of NHL are identified using histology, immunophenotype, and genetic studies. Pediatricians should promptly refer children and teenagers with a suspected NHL to a pediatric oncologist for evaluation and diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=see_link&amp;anchor=H25#H25\">",
"     \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\", section on 'Studies on excised tissue'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Specific subtypes of NHL have unique clinical and pathologic features. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Burkitt lymphoma",
"      </strong>",
"      &mdash; Burkitt lymphoma frequently presents with abdominal pain that mimics acute appendicitis or intussusception [",
"      <a class=\"abstract\" href=\"UTD.htm?10/1/10266/abstract/6\">",
"       6",
"      </a>",
"      ]. Rapidly growing lymphadenopathy in the head and neck region is also common. Less common sites of involvement are the testes, bone, skin, bone marrow, and central nervous system. Spontaneous tumor lysis syndrome is common. There is a male predominance and the peak age at presentation is four to six years old. &nbsp;(See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35720?source=see_link\">",
"       \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of Burkitt lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Diffuse large B cell lymphoma",
"      </strong>",
"      &mdash; Diffuse large B cell lymphoma has a variable presentation in children [",
"      <a class=\"abstract\" href=\"UTD.htm?10/1/10266/abstract/6\">",
"       6",
"      </a>",
"      ]. Patients may present with a rapidly enlarging symptomatic mass, most usually nodal enlargement in the neck or abdomen, or, in the case of primary mediastinal large B cell lymphoma, the mediastinum, but may present as a mass lesion anywhere in the body. Spontaneous tumor lysis syndrome is uncommon. Incidence increases with age. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24282?source=see_link\">",
"       \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       T cell lymphoblastic lymphoma",
"      </strong>",
"      &mdash; The most common presentation of T cell lymphoblastic lymphoma is that of peripheral lymphadenopathy, respiratory distress, wheezing, and superior vena cava syndrome from mediastinal involvement [",
"      <a class=\"abstract\" href=\"UTD.htm?10/1/10266/abstract/6\">",
"       6",
"      </a>",
"      ]. T cell lymphoblastic lymphoma is more common in males. The incidence is stable across all pediatric age groups with a median age of diagnosis of 12 years. Children diagnosed with lymphoblastic lymphoma whose bone marrow is more than 25 percent replaced by lymphoblasts are classified and treated as acute lymphoblastic leukemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/20/30023?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of precursor T cell acute lymphoblastic leukemia/lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Anaplastic large cell lymphoma",
"      </strong>",
"      &mdash; Anaplastic large cell lymphoma is a peripheral T cell lymphoma that typically presents as painless lymphadenopathy with or without skin or subcutaneous involvement. Fever and constitutional symptoms are frequent. The median age of presentation is also 12 years [",
"      <a class=\"abstract\" href=\"UTD.htm?10/1/10266/abstract/11\">",
"       11",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/47/25337?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of anaplastic large cell lymphoma, ALK positive\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1468730\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presenting symptoms and signs of NHL in children and adolescents may be caused by a variety of diseases and the differential diagnosis includes other malignant, infectious, and inflammatory diseases. They include Hodgkin lymphoma, metastatic adenopathy from other primary tumors (eg, nasopharyngeal carcinoma, soft tissue sarcoma), appendicitis, intussusception, toxoplasmosis, typical and atypical mycobacterium infections, EBV infection, systemic lupus erythematosus, and disorders causing reactive hyperplasia of lymph nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10266/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/22/33128?source=see_link\">",
"     \"Approach to the child with peripheral lymphadenopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30744?source=see_link\">",
"     \"Causes of peripheral lymphadenopathy in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/17/24857?source=see_link\">",
"     \"Diagnostic approach to and initial treatment of cervical lymphadenitis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/42/22185?source=see_link\">",
"     \"Evaluation of inguinal swelling in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/20/11593?source=see_link\">",
"     \"Causes of acute abdominal pain in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnostic considerations in patients with mediastinal masses depend upon the anatomic compartment in which the mass is located (",
"    <a class=\"graphic graphic_figure graphicRef88304 \" href=\"UTD.htm?26/2/26661\">",
"     figure 1",
"    </a>",
"    ). In children, anterior mediastinal mass must be distinguished from normal thymus, which attains maximal size when the child reaches approximately 10 years of age. Computed tomography",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other imaging studies may be necessary to make this distinction [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10266/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/24/31111?source=see_link\">",
"     \"Evaluation of mediastinal masses\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1876670\">",
"    <span class=\"h1\">",
"     STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;A complete evaluation of patients with suspected NHL is mandatory before beginning treatment. The goal is to evaluate the extent of disease, which in turn determines the clinical and pathologic stage, treatment, and, to a great extent, prognosis. This evaluation should be undertaken at a comprehensive pediatric oncology center. The superior results of children with malignancies treated in pediatric oncology centers as opposed to community hospitals is well documented [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10266/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1876649\">",
"     'Imaging studies'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In general, routine staging studies for pediatric NHL include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Contrast enhanced computerized tomographic (CT) imaging of the neck, chest, abdomen, and pelvis with or without integrated positron emission tomography (PET)",
"     </li>",
"     <li>",
"      Bilateral iliac crest bone marrow aspiration and biopsy",
"     </li>",
"     <li>",
"      Lumbar puncture for examination of cerebrospinal fluid",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Using information gathered from these studies, pediatric NHL is staged according to the Murphy Stage [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10266/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stage I &mdash; Stage I disease involves a single tumor (extranodal)",
"      <strong>",
"       or",
"      </strong>",
"      single anatomic area (nodal), excluding the abdomen and mediastinum. Features of stage II to IV disease described below must be absent.",
"     </li>",
"     <li>",
"      Stage II &mdash; Stage II disease is designated by any of the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Single extranodal area",
"      <strong>",
"       plus",
"      </strong>",
"      regional lymph nodes",
"     </li>",
"     <li>",
"      Two single extranodal tumors on the same side of the diaphragm with or without regional lymph nodes",
"     </li>",
"     <li>",
"      Primary gastrointestinal tumor (completely resected) with or without mesenteric lymph nodes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stage III &mdash; Stage III disease is designated by any one of the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Primary intrathoracic (mediastinal, thymic, pleural) disease",
"     </li>",
"     <li>",
"      Two extranodal sites on opposite sides of the diaphragm",
"     </li>",
"     <li>",
"      Extensive primary intra-abdominal disease",
"     </li>",
"     <li>",
"      Two or more nodal areas on opposite sides of the diaphragm",
"     </li>",
"     <li>",
"      Any paraspinal or epidural tumors",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stage IV &mdash; Any of the above with involvement of the bone marrow, central nervous system, or both",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1876677\">",
"    <span class=\"h1\">",
"     TREATMENT AND PROGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1469864\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with NHL should be treated in a comprehensive pediatric oncology center [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10266/abstract/16\">",
"     16",
"    </a>",
"    ]. Optimal therapy involves a multidisciplinary approach from the time of diagnosis, incorporating the skills of pediatric surgical subspecialists, radiation oncologists, pediatric medical",
"    <span class=\"nowrap\">",
"     oncologists/hematologists,",
"    </span>",
"    rehabilitation specialists, pediatric nurse specialists, and social workers experienced in the diagnosis and care of children with cancer. Assignment of stage and treatment are best determined after the multidisciplinary team has examined the patient and reviewed the diagnostic images and staging study results. Often there is no better therapy to offer a patient than enrollment onto a well-designed, scientifically valid, peer-reviewed clinical trial. Many of such trials are only offered at comprehensive pediatric oncology centers. (See",
"    <a class=\"local\" href=\"#H1469844\">",
"     'Clinical trials'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Combination chemotherapy is the primary modality used for the treatment of pediatric NHL. Unlike in adults, radiation therapy is not commonly used. As described in more detail below, studies in children have demonstrated that radiation therapy does not appear to improve outcomes in early stage NHL or as prophylaxis of the CNS [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10266/abstract/17-20\">",
"     17-20",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Most children and adolescents with NHL have a good prognosis with current therapy. Survival rates have improved dramatically over the past 40 years with modern treatment regimens resulting in estimated five-year survival rates of over 85 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10266/abstract/2,21\">",
"     2,21",
"    </a>",
"    ]. The preferred treatment regimen and expected outcome varies by histological subtype and stage. Outcomes are excellent (&gt;90 percent survival) for stage I or II pediatric NHL, regardless of histology. Stage III or IV pediatric NHL has long-term survival rates of 80 to 90 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22354031\">",
"    <span class=\"h2\">",
"     Acute toxicities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute effects of treatment for pediatric NHL depend upon the specific chemotherapeutic agents used.",
"   </p>",
"   <p>",
"    Myelosuppression is the most common dose-limiting acute toxicity of multiagent chemotherapy and can be treated with transfusions (red cells and platelets) or the administration of colony-stimulating factors (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/27/44470?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    ). Blood products, if given, need to be irradiated to prevent development of fatal transfusion-associated graft-versus-host disease in these immunocompromised subjects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/11/27832?source=see_link&amp;anchor=H8#H8\">",
"     \"Red cell transfusion in infants and children: Selection of blood products\", section on 'Irradiated red cells'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6710?source=see_link\">",
"     \"Transfusion-associated graft-versus-host disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chemotherapy-induced neutropenia and immunosuppression increase the risk of life-threatening infections with viruses, bacteria, and fungi, which need to be treated quickly and appropriately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15898?source=see_link&amp;anchor=H23804521#H23804521\">",
"     \"Fever in children with chemotherapy-induced neutropenia\", section on 'Overview of treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The cellular immune system, including decreased T cell and NK cell function, may be impaired at baseline and further compromised by myelosuppression, increasing the susceptibility to herpes zoster and varicella infections. Post-exposure prophylaxis can be used to prevent development of varicella infection in children who did not receive the",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/5/12374?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    before undergoing chemotherapy. Antiviral therapy should be promptly initiated in patients who develop varicella infection or varicella zoster. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/3/41016?source=see_link\">",
"     \"Post-exposure prophylaxis against varicella-zoster virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/20/33096?source=see_link\">",
"     \"Treatment of herpes zoster in the immunocompetent host\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children who receive multiple chemotherapeutic agents for the treatment of NHL may develop nausea and vomiting. These effects can be modulated with serotonin receptor antagonist anti-emetics",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pretreatment with benzodiazepines. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/18/39210?source=see_link\">",
"     \"Prevention and treatment of chemotherapy-induced nausea and vomiting\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other acute effects are related to particular agents. As examples,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/12/33993?source=see_link\">",
"     vincristine",
"    </a>",
"    is associated with neurotoxicity, and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/14/20711?source=see_link\">",
"     doxorubicin",
"    </a>",
"    with cardiac toxicity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/32/43530?source=see_link&amp;anchor=H20#H20\">",
"     \"Neurologic complications of non-platinum cancer chemotherapy\", section on 'Vincristine'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=see_link&amp;anchor=H36#H36\">",
"     \"Cardiotoxicity of anthracycline-like chemotherapy agents\", section on 'Issues in children'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1876685\">",
"    <span class=\"h2\">",
"     Lymphoblastic lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with lymphoblastic lymphoma should be enrolled in a clinical trial, whenever possible. The preferred treatment modality for pediatric lymphoblastic lymphoma is combination chemotherapy based on regimens used for acute lymphoblastic leukemia (ALL). With this approach, children with early stage (I or II) or advanced stage (III or IV) lymphoblastic lymphoma achieve survival rates of &gt;90 and &gt;80 percent, respectively. The role of surgery is limited to surgical biopsy of a peripheral lymph node, a bone marrow aspiration, or aspiration of pleural fluid to establish the diagnosis. There is no role for surgical debulking of disease due to the high sensitivity of the tumor to chemotherapy. Likewise, there is no routine need for radiation therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10266/abstract/22\">",
"     22",
"    </a>",
"    ]. Radiation is generally reserved for patients with pathologically proven involvement of the central nervous system (CNS) at the time of diagnosis. Testicular involvement at diagnosis does not require testicular radiation. &nbsp;",
"   </p>",
"   <p>",
"    Initial support for the use of ALL protocols in patients with lymphoblastic lymphoma was based upon the significant biological and clinical overlap between these two entities. Indeed, the WHO classification system considers these entities to be the same disease with different clinical presentations [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10266/abstract/10\">",
"     10",
"    </a>",
"    ]. Initial prospective trials demonstrated the efficacy of ALL protocols in patients with lymphoblastic lymphoma. Subsequent trials demonstrated that good outcomes can be maintained while decreasing the intensity of treatment. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the NHL-BFM-90 trial, 105 children with T cell lymphoblastic lymphoma received an eight-drug ALL induction regimen followed by consolidation therapy that included high dose",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/32/13833?source=see_link\">",
"       methotrexate",
"      </a>",
"      and maintenance therapy for a total treatment duration of two years [",
"      <a class=\"abstract\" href=\"UTD.htm?10/1/10266/abstract/23\">",
"       23",
"      </a>",
"      ]. Patients with stage III or IV disease also received prophylactic cranial irradiation, but no involved-field radiation. With a median follow-up of 4.5 years, estimated survival at five years was 90 percent. &nbsp;",
"     </li>",
"     <li>",
"      In the St. Jude NHL13 study, 41 children with advanced-stage lymphoblastic lymphoma were treated with a regimen used for T cell ALL that featured intensive intrathecal chemotherapy rather than prophylactic cranial irradiation [",
"      <a class=\"abstract\" href=\"UTD.htm?10/1/10266/abstract/19\">",
"       19",
"      </a>",
"      ]. With a median follow-up of 9.3 years, the estimated five-year survival rate was 90 percent.",
"     </li>",
"     <li>",
"      In the COG-A5971 trial, 60 children with stage I or II lymphoblastic lymphoma (75 percent B cell) were treated with a similar two-year ALL regimen without prophylactic cranial radiation [",
"      <a class=\"abstract\" href=\"UTD.htm?10/1/10266/abstract/24\">",
"       24",
"      </a>",
"      ]. At a median follow-up of 5.9 years, the estimated survival at five years was 96 percent. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Together, these and other trials demonstrate that treatment based upon protocols for ALL produce excellent survival rates among children with lymphoblastic lymphoma. Prophylactic cranial irradiation adds toxicity and can be eliminated for the vast majority of patients. For patients with disseminated T cell disease without CNS involvement at diagnosis, there appears to be no benefit to extra intensification of therapy during the induction or delayed intensification phases, and no benefit to using high dose",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/32/13833?source=see_link\">",
"     methotrexate",
"    </a>",
"    during interim maintenance [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10266/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who relapse do poorly due to difficulty obtaining a second remission. For patients who do obtain a second remission, allogeneic hematopoietic cell transplantation is the treatment of choice [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10266/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1876692\">",
"    <span class=\"h2\">",
"     Anaplastic large cell lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with anaplastic large cell lymphoma should be enrolled in a clinical trial, whenever possible. The preferred treatment modality is combination chemotherapy. The role of surgery is limited to surgical biopsy to establish the diagnosis. Radiation is rarely used. Central nervous system involvement is very rare.",
"   </p>",
"   <p>",
"    Experts differ in their preferred treatment protocol for pediatric anaplastic large cell lymphoma. Oncologists in the United States generally use prolonged intermittent therapy with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/12/33993?source=see_link\">",
"     vincristine",
"    </a>",
"    , an anthracycline, and steroids [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10266/abstract/27\">",
"     27",
"    </a>",
"    ]. In Europe, a more intense infusional therapy is administered over six months [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10266/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Both approaches produce a 65 to 75 percent five-year event-free survival [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10266/abstract/27-29\">",
"     27-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with recurrent disease may obtain prolonged remission following the administration of single agent",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/50/7975?source=see_link\">",
"     vinblastine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10266/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. In contrast, vinblastine does not appear to improve outcomes when used instead of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/12/33993?source=see_link\">",
"     vincristine",
"    </a>",
"    as initial therapy or as maintenance therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10266/abstract/28\">",
"     28",
"    </a>",
"    ]. Autologous and allogeneic hematopoietic cell transplantation (HCT) can also produce prolonged remissions in relapsed patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10266/abstract/26,32-34\">",
"     26,32-34",
"    </a>",
"    ]. When compared with allogeneic HCT, autologous HCT is associated with a higher risk of recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10266/abstract/26\">",
"     26",
"    </a>",
"    ]. However, it is unclear whether the lower rate of relapse with allogeneic HCT translates into a survival benefit.",
"   </p>",
"   <p>",
"    Two targeted therapies have demonstrated significant initial activity in relapsed anaplastic large cell lymphoma:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/6/16486?source=see_link\">",
"       Brentuximab vedotin",
"      </a>",
"      is an immunotoxin with a CD-30 directed antibody linked to the antitubulin agent monomethyl auristatin E [",
"      <a class=\"abstract\" href=\"UTD.htm?10/1/10266/abstract/35\">",
"       35",
"      </a>",
"      ]. Brentuximab vedotin is approved by the US Food and Drug Administration for the treatment of adults with systemic anaplastic large cell lymphoma after failure of at least one prior multi-agent chemotherapy regimen [",
"      <a class=\"abstract\" href=\"UTD.htm?10/1/10266/abstract/36\">",
"       36",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27785?source=see_link&amp;anchor=H4185630#H4185630\">",
"       \"Treatment of relapsed or refractory peripheral T cell lymphoma\", section on 'Brentuximab'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/58/30631?source=see_link\">",
"       Crizotinib",
"      </a>",
"      is a small molecule inhibitor of the ALK tyrosine kinase that has demonstrated activity in a subset of patients with non-small cell lung cancer. Case reports have described responses in patients with multiply relapsed ALK positive anaplastic large cell lymphoma [",
"      <a class=\"abstract\" href=\"UTD.htm?10/1/10266/abstract/37,38\">",
"       37,38",
"      </a>",
"      ]. Further studies of this agent in ALK positive anaplastic large cell lymphoma are underway. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27785?source=see_link&amp;anchor=H25702125#H25702125\">",
"       \"Treatment of relapsed or refractory peripheral T cell lymphoma\", section on 'Crizotinib'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1876699\">",
"    <span class=\"h2\">",
"     Burkitt lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with Burkitt lymphoma should be enrolled in a clinical trial, whenever possible. The preferred treatment modality is multi-agent combination chemotherapy with or without immunotherapy (ie,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/47/34551?source=see_link\">",
"     rituximab",
"    </a>",
"    ). There is no role for large surgical debulking procedures due to the exquisite sensitivity of Burkitt cells to chemotherapy. However, it is not uncommon for Burkitt lymphoma to be discovered during surgery for acute abdominal symptoms, especially when it occurs in the ileocecal region. Similarly, Burkitt lymphoma that presents as asymmetrical enlargement of the tonsils is often diagnosed during tonsillectomy. If the surgeons can remove the tumor entirely, it is appropriate to do so in such situations.",
"   </p>",
"   <p>",
"    The mainstay of therapy for Burkitt lymphoma is chemotherapy of six weeks to eight months duration, depending on the stage of disease. With this strategy, children with early stage (I or II) completely resected Burkitt lymphoma have estimated four-year event-free survival of 98 percent and four-year overall survival of 99 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10266/abstract/39\">",
"     39",
"    </a>",
"    ]. Children with unresected early stage or advanced stage (III) disease that does not involve the CNS or bone marrow have estimated four-year event-free and overall survival of over 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10266/abstract/40\">",
"     40",
"    </a>",
"    ]. Patients presenting with stage IV disease, especially those with CNS involvement, exhibit a worse prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10266/abstract/41\">",
"     41",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    There are limited data evaluating the role of the recombinant anti-CD20 antibody",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/47/34551?source=see_link\">",
"     rituximab",
"    </a>",
"    in the treatment of Burkitt lymphoma. This is an attractive addition to conventional chemotherapy given the great successes with rituximab in other NHL subtypes in adults and the expression of the CD-20 antigen in most cases of Burkitt lymphoma. There are few studies of rituximab in children with Burkitt lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10266/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. These studies suggest that rituximab has good single agent activity in previously untreated patients and that it is safe when used in combination with intensive infusional chemotherapy for children with advanced Burkitt lymphoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/23/36217?source=see_link&amp;anchor=H8#H8\">",
"     \"Treatment of Burkitt leukemia/lymphoma in adults\", section on 'Rituximab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among children with Burkitt lymphoma, relapses typically occur within the first two years and are clinically aggressive. The outcome of children with relapsed Burkitt lymphoma is poor, usually due to failure to achieve a second remission.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/47/34551?source=see_link\">",
"     Rituximab",
"    </a>",
"    plus ICE (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/33/11800?source=see_link\">",
"     ifosfamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/10/43174?source=see_link\">",
"     carboplatin",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/17/41240?source=see_link\">",
"     etoposide",
"    </a>",
"    ) was effective in a small study of children with relapsed mature B cell lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10266/abstract/44\">",
"     44",
"    </a>",
"    ]. Both autologous and allogeneic hematopoietic cell transplantation play a role in salvage therapy for the patient who has chemotherapy sensitive disease following relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10266/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1876706\">",
"    <span class=\"h2\">",
"     Diffuse large B cell lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with diffuse large B cell lymphoma (DLBCL) should be enrolled in a clinical trial whenever possible. Children with DLBCL are treated with regimens used for Burkitt lymphoma. This differs from the management of DLBCL in adults where patients with DLBCL and patients with Burkitt lymphoma are treated with different regimens.",
"   </p>",
"   <p>",
"    Older adolescents with DLBCL may be treated with pediatric regimens or with adult regimens. However, the standard adult regimen R-CHOP (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/47/34551?source=see_link\">",
"     rituximab",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/14/20711?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/12/33993?source=see_link\">",
"     vincristine",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    ) would expose the patient to higher doses of anthracycline than used in pediatric Burkitt lymphoma protocols. In one study, gene expression profiles were able to distinguish pediatric DLBCL from pediatric Burkitt lymphoma, but also identified minor differences between pediatric DLBCL and adult DLBCL [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10266/abstract/45\">",
"     45",
"    </a>",
"    ]. These results suggest the pediatric and adult cases have distinct pathogenetic mechanisms. (See",
"    <a class=\"local\" href=\"#H1876699\">",
"     'Burkitt lymphoma'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26330?source=see_link\">",
"     \"Initial treatment of advanced stage diffuse large B cell lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/12/18634?source=see_link\">",
"     \"Initial treatment of limited stage diffuse large B cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1876713\">",
"    <span class=\"h2\">",
"     Rare pediatric NHL variants",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, the most common subtypes of pediatric NHL are Burkitt lymphoma, diffuse large B cell lymphoma, lymphoblastic T cell or B cell lymphoma, and anaplastic large cell lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10266/abstract/6\">",
"     6",
"    </a>",
"    ]. Other subtypes (eg, follicular lymphoma, marginal zone lymphoma) are less common, accounting for approximately 7 percent of pediatric NHL.",
"   </p>",
"   <p>",
"    Primary mediastinal B cell lymphoma is a mature B cell neoplasm presenting in the mediastinum that is morphologically, genetically, and biologically different from other mature B cell neoplasms seen in pediatric patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10266/abstract/10,46-48\">",
"     10,46-48",
"    </a>",
"    ]. It is most common in adolescent patients, particularly women. Dose adjusted EPOCH is included in an ongoing international B cell clinical trial for adolescents with primary mediastinal B cell lymphoma (NCT01516567) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10266/abstract/49\">",
"     49",
"    </a>",
"    ]. The use of radiation therapy in this disease remains controversial.",
"   </p>",
"   <p>",
"    Follicular lymphoma, marginal zone lymphoma, and peripheral T cell lymphomas also occur in pediatric patients. Therapy is often based on treatment literature in adults. Of note, follicular lymphoma and marginal zone lymphomas in pediatrics often demonstrate better outcomes than their adult counterparts. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9865?source=see_link\">",
"     \"Initial treatment of limited stage (I/II) follicular lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/17/18714?source=see_link\">",
"     \"Initial treatment of advanced stage (III/IV) follicular lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22169?source=see_link\">",
"     \"Treatment of marginal zone (MALT) lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33065?source=see_link\">",
"     \"Initial treatment of peripheral T cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1876720\">",
"    <span class=\"h1\">",
"     SPECIAL POPULATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1883012\">",
"    <span class=\"h2\">",
"     Lymphoproliferative disease in the immune compromised patient",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of lymphoproliferative disease or lymphoma is 100-fold higher in immunocompromised children than in the general population. The cause of such immune deficiencies may be a genetically inherited defect [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10266/abstract/50\">",
"     50",
"    </a>",
"    ], secondary to human immunodeficiency virus (HIV) infection [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10266/abstract/51\">",
"     51",
"    </a>",
"    ], or iatrogenic following transplantation (solid organ transplantation or allogeneic hematopoietic cell transplantation [HCT]) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10266/abstract/52\">",
"     52",
"    </a>",
"    ]. Epstein-Barr virus (EBV) is associated with most of these tumors, but some tumors are not associated with any infectious agent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/63/31738?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of post-transplant lymphoproliferative disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    NHL observed in primary immunodeficiency usually shows a mature B cell phenotype and large cell histology [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10266/abstract/50\">",
"     50",
"    </a>",
"    ]. Children with primary immunodeficiency and NHL are more likely to have high-stage disease and present with symptoms related to extranodal disease, particularly the gastrointestinal tract and central nervous system. Patients with primary immunodeficiency often require allogeneic HCT to restore sufficient immunity to prevent recurrences. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/2/1066?source=see_link\">",
"     \"Hematopoietic cell transplantation for primary immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    NHL is an AIDS-defining malignancy. A key component of the treatment of all HIV-infected patients with an AIDS-related NHL is the administration of highly active antiretroviral therapy (HAART). The reduction in HIV viral load and improvement in immune function associated with HAART is expected to result in better tolerance of chemotherapy, fewer opportunistic infections, and improvement in overall treatment outcome. As such, children with HIV and NHL should be treated with standard chemotherapy regimens for NHL, but careful attention to prophylaxis against and early detection of infection is warranted. The treatment of AIDS-related lymphomas in adults is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38346?source=see_link\">",
"     \"AIDS-related lymphomas: Treatment of systemic lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Post-transplant lymphoproliferative disease (PTLD) represents a spectrum of clinically and morphologically heterogeneous lymphoid proliferations, ranging from disease that looks like a normal reactive process to disease that looks like NHL. Essentially all PTLD following HCT is associated with EBV, but EBV-negative PTLD can be seen following solid organ transplant. In PTLD, first-line therapy is the reduction of immunosuppression. Low-dose chemotherapy or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/47/34551?source=see_link\">",
"     rituximab",
"    </a>",
"    , an anti-CD20 antibody, have been used with some success where reduction of immunosuppression has failed to cure the disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=see_link\">",
"     \"Treatment and prevention of post-transplant lymphoproliferative disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1876736\">",
"    <span class=\"h2\">",
"     Adolescent and young adult NHL",
"    </span>",
"    &nbsp;&mdash;&nbsp;NHL diagnosed in adolescent and young adults (AYA) includes a higher percentage of subtypes typically seen in adulthood. The most common NHL in AYA is diffuse large B cell lymphoma, followed by follicular lymphoma, Burkitt lymphoma, lymphoblastic lymphoma and then mycosis fungoides [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10266/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. There is a paucity of data regarding the preferred treatment regimens for AYA with NHL. Older adolescents may be treated with pediatric regimens or with adult regimens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1876743\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;After completion of the initially planned therapy, patients should be evaluated to determine the disease response to treatment and should be followed longitudinally for relapse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1876751\">",
"    <span class=\"h2\">",
"     Assessing treatment response",
"    </span>",
"    &nbsp;&mdash;&nbsp;The post-treatment imaging study of choice is the",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    scan, which provides information on the size and activity of residual masses. Patients who have no evidence of residual disease upon restaging are seen at periodic intervals to monitor for relapse. Residual masses should be biopsied to distinguish between residual disease and other masses (eg, fibrosis, thymus). Relapsed disease can be suggested by changes on imaging studies, but can only be confirmed by biopsy. As such, a biopsy should always be obtained to document relapsed disease before proceeding to salvage therapy.",
"   </p>",
"   <p>",
"    In a prospective study, 34 children with nonlymphoblastic NHL underwent imaging with",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    and conventional contrast material-enhanced CT at baseline, after two cycles of chemotherapy, and after completion of chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/1/10266/abstract/55\">",
"     55",
"    </a>",
"    ]. Baseline",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    and conventional CT were concordant in 112 disease sites, while",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    depicted 18 more disease sites and two fewer disease sites resulting in disease upstaging in five patients, but no change in treatment. There was 100 percent concordance regarding bone marrow involvement between",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    and bone marrow biopsy. Interim imaging did not predict progression-free or overall survival. Both post-treatment",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    and CT could predict progression-free survival, but only post-treatment contrast-enhanced CT could predict overall survival.",
"   </p>",
"   <p>",
"    A discussion of the accuracy of",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    in the follow-up of adults with lymphoma is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=see_link&amp;anchor=H17#H17\">",
"     \"Initial evaluation and staging of non-Hodgkin lymphoma\", section on 'Evaluating response to treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1876758\">",
"    <span class=\"h2\">",
"     Long-term toxicities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Survivors of childhood cancer are at increased risk for long-term sequelae. Late adverse effects are primarily dependent upon the type and intensity of therapy. Patients who received more intense chemotherapy are more likely to have late complications. The late effects consist primarily of those related to anthracycline and alkylating toxicity. Radiation therapy plays a limited role in treatment, thus most patients do not face the long-term effects of radiation.",
"   </p>",
"   <p>",
"    The late effects of treatment for pediatric NHL are primarily related to anthracycline and alkylating agent exposure, and include an increased incidence of infertility, second cancers, and congestive heart failure. Patients with lymphoblastic lymphoma receive treatment similar to children with acute lymphoblastic leukemia. Specific long-term follow-up guidelines after treatment of childhood cancer have been published by the Children's Oncology Group, and are available at",
"    <a class=\"external\" href=\"file://www.survivorshipguidelines.org/\">",
"     www.survivorshipguidelines.org",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    A subset of patients is treated with hematopoietic cell transplantation. These therapies place NHL survivors at risk for the development of a diverse array of long-term sequelae, with the potential to negatively impact both their quality of life and ultimately their survival. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/44/35530?source=see_link\">",
"     \"The approach to hematopoietic cell transplantation survivorship\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1469844\">",
"    <span class=\"h1\">",
"     CLINICAL TRIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;All children with NHL should be considered for entry into a clinical trial. Trials are designed to compare potentially better therapy with that which is currently accepted as standard. Additional information and instructions for referring a patient to an appropriate research center can be obtained from the United States National Institutes of Health (",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov/\">",
"     www.clinicaltrials.gov",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1876765\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Non-Hodgkin lymphoma (NHL) consists of a diverse group of malignant neoplasms of the lymphoid tissues variously derived from B cell progenitors, T cell progenitors, mature B cells, or mature T cells. Unlike in adults where low-grade, clinically indolent NHL subtypes predominate, most pediatric NHL cases are of high-grade and have an aggressive clinical behavior. (See",
"      <a class=\"local\" href=\"#H1876620\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical presentation of pediatric NHL varies depending upon the type of lymphoma and the areas of involvement. Signs and symptoms develop quickly, usually over a few weeks to months. NHL commonly presents as enlarging, non-tender lymphadenopathy or as symptoms due to the compression of surrounding structures, such as new onset wheezing, facial swelling, respiratory distress, asymmetrical tonsils, or acute abdominal pain. (See",
"      <a class=\"local\" href=\"#H1876635\">",
"       'Signs and symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Potentially emergent complications of NHL may be present at the time of diagnosis and need to be considered during the initial workup and evaluation of a patient with suspected pediatric NHL. These may be life-threatening and include but are not limited to superior vena cava obstruction, acute airway obstruction, and tumor lysis syndrome. Prompt recognition and therapy are critical. (See",
"      <a class=\"local\" href=\"#H1468535\">",
"       'Oncologic emergencies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pediatricians should promptly refer children and teenagers with a suspected NHL to a pediatric oncologist for evaluation and diagnosis. The diagnosis of NHL is based upon the pathologic evaluation of involved tissue, usually an abdominal mass, extranodal site, or lymph node, interpreted within the clinical context. Subtypes of NHL are identified using histology, immunophenotype, and genetic studies. (See",
"      <a class=\"local\" href=\"#H1876663\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Combination chemotherapy is the primary modality used for the treatment of pediatric NHL. The role of surgery is limited to surgical biopsy of a peripheral lymph node, a bone marrow aspiration, or aspiration of pleural fluid to establish the diagnosis. Unlike in adults, radiation therapy is not commonly used. (See",
"      <a class=\"local\" href=\"#H1469864\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most children and adolescents with NHL have a good prognosis with current therapy. Long-term overall survival is achieved in &gt;80 percent of pediatric NHL cases overall, and in &gt;90 percent of stage I or II pediatric NHL. (See",
"      <a class=\"local\" href=\"#H1469864\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Survivors of childhood cancer are at increased risk for long-term sequelae. Late adverse effects are primarily dependent upon the type and intensity of therapy. The late effects of treatment for pediatric NHL consist primarily of those related to anthracycline and alkylating agent exposure. Specific long-term follow-up guidelines after treatment of childhood cancer have been published by the Children's Oncology Group, and are available at",
"      <a class=\"external\" href=\"file://www.survivorshipguidelines.org/\">",
"       www.survivorshipguidelines.org",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H1876758\">",
"       'Long-term toxicities'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10266/abstract/1\">",
"      Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006; 107:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10266/abstract/2\">",
"      Kaatsch P. Epidemiology of childhood cancer. Cancer Treat Rev 2010; 36:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10266/abstract/3\">",
"      Crump C, Sundquist K, Sieh W, et al. Perinatal and family risk factors for non-Hodgkin lymphoma in early life: a Swedish national cohort study. J Natl Cancer Inst 2012; 104:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10266/abstract/4\">",
"      Steliarova-Foucher E, Stiller C, Kaatsch P, et al. Geographical patterns and time trends of cancer incidence and survival among children and adolescents in Europe since the 1970s (the ACCISproject): an epidemiological study. Lancet 2004; 364:2097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10266/abstract/5\">",
"      Emmanuel B, Anderson WF. Non-Hodgkin lymphoma in early life. J Natl Cancer Inst 2012; 104:888.",
"     </a>",
"    </li>",
"    <li>",
"     Percy CL, Smith MA, Linet M, et al. Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. NIH Pub.No. 99-4649., pp 35-50, National Cancer Institute, SEER Program; National Cancer Institute, Bethesda, MD 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10266/abstract/7\">",
"      Salzburg J, Burkhardt B, Zimmermann M, et al. Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma subtype: a Berlin-Frankfurt-Munster Group Report. J Clin Oncol 2007; 25:3915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10266/abstract/8\">",
"      Cairo MS, Sposto R, Gerrard M, et al. Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (&ge; 15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB LMB 96 study. J Clin Oncol 2012; 30:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10266/abstract/9\">",
"      Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007; 25:571.",
"     </a>",
"    </li>",
"    <li>",
"     Swerdlow SH, Campo E, Harris NL, et al. World Health Organization classification of tumours of haematopoietic and lymphoid tissues, IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10266/abstract/11\">",
"      Sandlund JT, Downing JR, Crist WM. Non-Hodgkin's lymphoma in childhood. N Engl J Med 1996; 334:1238.",
"     </a>",
"    </li>",
"    <li>",
"     Sills RH. The spleen and lymph nodes. In: Oski's Pediatrics. Principles and Practice, 4th ed, McMillan JA, Feigin RD, DeAngelis C, Jones MD (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia 2006. p.1717.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10266/abstract/13\">",
"      Heiberg E, Wolverson MK, Sundaram M, Nouri S. Normal thymus: CT characteristics in subjects under age 20. AJR Am J Roentgenol 1982; 138:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10266/abstract/14\">",
"      Murphy SB. The national impact of clinical cooperative group trials for pediatric cancer. Med Pediatr Oncol 1995; 24:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10266/abstract/15\">",
"      Murphy SB. Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: dissimilarities from lymphomas in adults. Semin Oncol 1980; 7:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10266/abstract/16\">",
"      Corrigan JJ, Feig SA, American Academy of Pediatrics. Guidelines for pediatric cancer centers. Pediatrics 2004; 113:1833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10266/abstract/17\">",
"      Link MP, Shuster JJ, Donaldson SS, et al. Treatment of children and young adults with early-stage non-Hodgkin's lymphoma. N Engl J Med 1997; 337:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10266/abstract/18\">",
"      Burkhardt B, Woessmann W, Zimmermann M, et al. Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system-negative stage III or IV lymphoblastic lymphoma. J Clin Oncol 2006; 24:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10266/abstract/19\">",
"      Sandlund JT, Pui CH, Zhou Y, et al. Effective treatment of advanced-stage childhood lymphoblastic lymphoma without prophylactic cranial irradiation: results of St Jude NHL13 study. Leukemia 2009; 23:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10266/abstract/20\">",
"      Seidemann K, Tiemann M, Schrappe M, et al. Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-M&uuml;nster Group Trial NHL-BFM 90. Blood 2001; 97:3699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10266/abstract/21\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10266/abstract/22\">",
"      Jairam V, Roberts KB, Yu JB. Historical trends in the use of radiation therapy for pediatric cancers: 1973-2008. Int J Radiat Oncol Biol Phys 2013; 85:e151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10266/abstract/23\">",
"      Reiter A, Schrappe M, Ludwig WD, et al. Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood 2000; 95:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10266/abstract/24\">",
"      Termuhlen AM, Smith LM, Perkins SL, et al. Outcome of newly diagnosed children and adolescents with localized lymphoblastic lymphoma treated on Children's Oncology Group trial A5971: a report from the Children's Oncology Group. Pediatr Blood Cancer 2012; 59:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10266/abstract/25\">",
"      Abromowitch M, Termuhlen A, Chang M, et al. High-dose methotrexate and early intensification of therapy do not improve 3 year EFS in children and adolescents with disseminated lymphoblastic lymphoma: Results of the randomized arms of COG A5971. Blood 2008; 112:abstract 3610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10266/abstract/26\">",
"      Gross TG, Hale GA, He W, et al. Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents. Biol Blood Marrow Transplant 2010; 16:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10266/abstract/27\">",
"      Laver JH, Kraveka JM, Hutchison RE, et al. Advanced-stage large-cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: a Pediatric Oncology Group phase III trial. J Clin Oncol 2005; 23:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10266/abstract/28\">",
"      Le Deley MC, Rosolen A, Williams DM, et al. Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: results of the randomized ALCL99-vinblastine trial. J Clin Oncol 2010; 28:3987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10266/abstract/29\">",
"      Pillon M, Gregucci F, Lombardi A, et al. Results of AIEOP LNH-97 protocol for the treatment of anaplastic large cell lymphoma of childhood. Pediatr Blood Cancer 2012; 59:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10266/abstract/30\">",
"      Brugi&egrave;res L, Quartier P, Le Deley MC, et al. Relapses of childhood anaplastic large-cell lymphoma: treatment results in a series of 41 children--a report from the French Society of Pediatric Oncology. Ann Oncol 2000; 11:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10266/abstract/31\">",
"      Brugi&egrave;res L, Pacquement H, Le Deley MC, et al. Single-drug vinblastine as salvage treatment for refractory or relapsed anaplastic large-cell lymphoma: a report from the French Society of Pediatric Oncology. J Clin Oncol 2009; 27:5056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10266/abstract/32\">",
"      Woessmann W, Peters C, Lenhard M, et al. Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents--a Berlin-Frankfurt-M&uuml;nster group report. Br J Haematol 2006; 133:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10266/abstract/33\">",
"      Harris RE, Termuhlen AM, Smith LM, et al. Autologous peripheral blood stem cell transplantation in children with refractory or relapsed lymphoma: results of Children's Oncology Group study A5962. Biol Blood Marrow Transplant 2011; 17:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10266/abstract/34\">",
"      Woessmann W, Zimmermann M, Lenhard M, et al. Relapsed or refractory anaplastic large-cell lymphoma in children and adolescents after Berlin-Frankfurt-Muenster (BFM)-type first-line therapy: a BFM-group study. J Clin Oncol 2011; 29:3065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10266/abstract/35\">",
"      Okeley NM, Miyamoto JB, Zhang X, et al. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res 2010; 16:888.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125388s000,125399s000lbl.pdf (Accessed on August 22, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10266/abstract/37\">",
"      Gambacorti-Passerini C, Messa C, Pogliani EM. Crizotinib in anaplastic large-cell lymphoma. N Engl J Med 2011; 364:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10266/abstract/38\">",
"      Foyil KV, Bartlett NL. Brentuximab vedotin and crizotinib in anaplastic large-cell lymphoma. Cancer J 2012; 18:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10266/abstract/39\">",
"      Gerrard M, Cairo MS, Weston C, et al. Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study. Br J Haematol 2008; 141:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10266/abstract/40\">",
"      Patte C, Auperin A, Gerrard M, et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood 2007; 109:2773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10266/abstract/41\">",
"      Cairo MS, Gerrard M, Sposto R, et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood 2007; 109:2736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10266/abstract/42\">",
"      Meinhardt A, Burkhardt B, Zimmermann M, et al. Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia. J Clin Oncol 2010; 28:3115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10266/abstract/43\">",
"      Akbayram S, Do��an M, Akg&uuml;n C, et al. Use of rituximab in three children with relapsed/refractory Burkitt lymphoma. Target Oncol 2010; 5:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10266/abstract/44\">",
"      Griffin TC, Weitzman S, Weinstein H, et al. A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer 2009; 52:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10266/abstract/45\">",
"      Deffenbacher KE, Iqbal J, Sanger W, et al. Molecular distinctions between pediatric and adult mature B-cell non-Hodgkin lymphomas identified through genomic profiling. Blood 2012; 119:3757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10266/abstract/46\">",
"      Oschlies I, Burkhardt B, Salaverria I, et al. Clinical, pathological and genetic features of primary mediastinal large B-cell lymphomas and mediastinal gray zone lymphomas in children. Haematologica 2011; 96:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10266/abstract/47\">",
"      Seidemann K, Tiemann M, Lauterbach I, et al. Primary mediastinal large B-cell lymphoma with sclerosis in pediatric and adolescent patients: treatment and results from three therapeutic studies of the Berlin-Frankfurt-M&uuml;nster Group. J Clin Oncol 2003; 21:1782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10266/abstract/48\">",
"      Gerrard M, Waxman IM, Sposto R, et al. Outcome and pathologic classification of children and adolescents with mediastinal large B-cell lymphoma treated with FAB/LMB96 mature B-NHL therapy. Blood 2013; 121:278.",
"     </a>",
"    </li>",
"    <li>",
"     file://clinicaltrials.gov/show/NCT01516567 (Accessed on February 22, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10266/abstract/50\">",
"      Seidemann K, Tiemann M, Henze G, et al. Therapy for non-Hodgkin lymphoma in children with primary immunodeficiency: analysis of 19 patients from the BFM trials. Med Pediatr Oncol 1999; 33:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10266/abstract/51\">",
"      Biggar RJ, Frisch M, Goedert JJ. Risk of cancer in children with AIDS. AIDS-Cancer Match Registry Study Group. JAMA 2000; 284:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10266/abstract/52\">",
"      Schober T, Framke T, Kreipe H, et al. Characteristics of early and late PTLD development in pediatric solid organ transplant recipients. Transplantation 2013; 95:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10266/abstract/53\">",
"      Jaglowski SM, Linden E, Termuhlen AM, Flynn JM. Lymphoma in adolescents and young adults. Semin Oncol 2009; 36:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10266/abstract/54\">",
"      Hochberg J, Waxman IM, Kelly KM, et al. Adolescent non-Hodgkin lymphoma and Hodgkin lymphoma: state of the science. Br J Haematol 2009; 144:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/1/10266/abstract/55\">",
"      Bakhshi S, Radhakrishnan V, Sharma P, et al. Pediatric nonlymphoblastic non-Hodgkin lymphoma: baseline, interim, and posttreatment PET/CT versus contrast-enhanced CT for evaluation--a prospective study. Radiology 2012; 262:956.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13940 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.69.132.100-4DCBBA35C4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_1_10266=[""].join("\n");
var outline_f10_1_10266=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1876765\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1876613\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1876620\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1876627\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1468535\">",
"      Oncologic emergencies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1876635\">",
"      Signs and symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1876642\">",
"      Laboratory features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1876649\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1876663\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1468730\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1876670\">",
"      STAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1876677\">",
"      TREATMENT AND PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1469864\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22354031\">",
"      Acute toxicities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1876685\">",
"      Lymphoblastic lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1876692\">",
"      Anaplastic large cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1876699\">",
"      Burkitt lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1876706\">",
"      Diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1876713\">",
"      Rare pediatric NHL variants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1876720\">",
"      SPECIAL POPULATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1883012\">",
"      Lymphoproliferative disease in the immune compromised patient",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1876736\">",
"      Adolescent and young adult NHL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1876743\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1876751\">",
"      Assessing treatment response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1876758\">",
"      Long-term toxicities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1469844\">",
"      CLINICAL TRIALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1876765\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/13940\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/13940|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/2/26661\" title=\"figure 1\">",
"      Mediastinal mass anatomic compartments",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38346?source=related_link\">",
"      AIDS-related lymphomas: Treatment of systemic lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=related_link\">",
"      Anemia of chronic disease (anemia of chronic inflammation)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/22/33128?source=related_link\">",
"      Approach to the child with peripheral lymphadenopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/24/1416?source=related_link\">",
"      Asymptomatic hyperuricemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/60/23497?source=related_link\">",
"      Ataxia-telangiectasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=related_link\">",
"      Cardiotoxicity of anthracycline-like chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/20/11593?source=related_link\">",
"      Causes of acute abdominal pain in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30744?source=related_link\">",
"      Causes of peripheral lymphadenopathy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21337?source=related_link\">",
"      Classification of the hematopoietic neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/47/25337?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of anaplastic large cell lymphoma, ALK positive",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/20/30023?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of precursor T cell acute lymphoblastic leukemia/lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=related_link\">",
"      Clinical presentation and diagnosis of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/17/24857?source=related_link\">",
"      Diagnostic approach to and initial treatment of cervical lymphadenitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41129?source=related_link\">",
"      Emergencies in pediatric cancer patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/63/31738?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of post-transplant lymphoproliferative disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35720?source=related_link\">",
"      Epidemiology, clinical manifestations, pathologic features, and diagnosis of Burkitt lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24282?source=related_link\">",
"      Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/42/22185?source=related_link\">",
"      Evaluation of inguinal swelling in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/24/31111?source=related_link\">",
"      Evaluation of mediastinal masses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15898?source=related_link\">",
"      Fever in children with chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23914?source=related_link\">",
"      Hematologic consequences of malignancy: Anemia and bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/2/1066?source=related_link\">",
"      Hematopoietic cell transplantation for primary immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=related_link\">",
"      Initial evaluation and staging of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/17/18714?source=related_link\">",
"      Initial treatment of advanced stage (III/IV) follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26330?source=related_link\">",
"      Initial treatment of advanced stage diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9865?source=related_link\">",
"      Initial treatment of limited stage (I/II) follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/12/18634?source=related_link\">",
"      Initial treatment of limited stage diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33065?source=related_link\">",
"      Initial treatment of peripheral T cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/32/43530?source=related_link\">",
"      Neurologic complications of non-platinum cancer chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/6/32874?source=related_link\">",
"      Overview of Hodgkin lymphoma in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/3/41016?source=related_link\">",
"      Post-exposure prophylaxis against varicella-zoster virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/18/39210?source=related_link\">",
"      Prevention and treatment of chemotherapy-induced nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/11/27832?source=related_link\">",
"      Red cell transfusion in infants and children: Selection of blood products",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/17/39194?source=related_link\">",
"      Secondary involvement of the central nervous system by non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/44/35530?source=related_link\">",
"      The approach to hematopoietic cell transplantation survivorship",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6710?source=related_link\">",
"      Transfusion-associated graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=related_link\">",
"      Treatment and prevention of post-transplant lymphoproliferative disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/23/36217?source=related_link\">",
"      Treatment of Burkitt leukemia/lymphoma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/20/33096?source=related_link\">",
"      Treatment of herpes zoster in the immunocompetent host",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22169?source=related_link\">",
"      Treatment of marginal zone (MALT) lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27785?source=related_link\">",
"      Treatment of relapsed or refractory peripheral T cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=related_link\">",
"      Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3402?source=related_link\">",
"      Tumor lysis syndrome: Prevention and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27541?source=related_link\">",
"      Uric acid renal diseases",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_1_10267="Manifestations of fibromyalgia";
var content_f10_1_10267=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F60339&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F60339&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Manifestations of fibromyalgia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        History",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Female, usually age 20 to 65",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic, generalized pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fatigue",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sleep and mood disturbances",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Headaches",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Irritable bowel syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Physical examination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multiple tender areas of muscle and tendons",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No inflammatory muscle or joint disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Laboratory tests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unremarkable",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_1_10267=[""].join("\n");
var outline_f10_1_10267=null;
var title_f10_1_10268="Dis prog gastric GIST";
var content_f10_1_10268=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F78594&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F78594&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Disease progression rate for gastric gastrointestinal stromal tumors (GIST)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Stage",
"      </td>",
"      <td class=\"subtitle1\">",
"       Tumor size, cm",
"      </td>",
"      <td class=\"subtitle1\">",
"       Mitotic rate",
"      </td>",
"      <td class=\"subtitle1\">",
"       Prognostic group",
"       <sup>",
"        [1]",
"       </sup>",
"      </td>",
"      <td class=\"subtitle1\">",
"       Observed rate of progressive disease",
"       <sup>",
"        [1]",
"       </sup>",
"       , percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       IA",
"      </td>",
"      <td>",
"       &le;5",
"      </td>",
"      <td>",
"       Low",
"      </td>",
"      <td>",
"       1, 2",
"      </td>",
"      <td>",
"       0-2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       IB",
"      </td>",
"      <td>",
"       &gt;5-10",
"      </td>",
"      <td>",
"       Low",
"      </td>",
"      <td>",
"       3a",
"      </td>",
"      <td>",
"       3-4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"3\">",
"       II",
"      </td>",
"      <td>",
"       &gt;5-10",
"      </td>",
"      <td>",
"       High",
"      </td>",
"      <td>",
"       4",
"      </td>",
"      <td>",
"       Insufficient data",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &gt;5-10",
"      </td>",
"      <td>",
"       High",
"      </td>",
"      <td>",
"       5",
"      </td>",
"      <td>",
"       15",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &gt;10",
"      </td>",
"      <td>",
"       Low",
"      </td>",
"      <td>",
"       3b",
"      </td>",
"      <td>",
"       12",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       IIIA",
"      </td>",
"      <td>",
"       &gt;5-10",
"      </td>",
"      <td>",
"       High",
"      </td>",
"      <td>",
"       6a",
"      </td>",
"      <td>",
"       49",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       IIIB",
"      </td>",
"      <td>",
"       &gt;10",
"      </td>",
"      <td>",
"       High",
"      </td>",
"      <td>",
"       6b",
"      </td>",
"      <td>",
"       86",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reference:",
"     <ol>",
"      <li>",
"       Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic studies of 1765 cases with long-term follow-up. Am J Surg Pathol. 2005; 29:52-68, with permission from Lippincott Williams &amp; Wilkins.",
"      </li>",
"     </ol>",
"     Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_1_10268=[""].join("\n");
var outline_f10_1_10268=null;
var title_f10_1_10269="Gender nonconformity terminology";
var content_f10_1_10269=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F86993&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F86993&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Terms used to describe various aspects of gender and sexuality*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"20%\">",
"     </colgroup>",
"     <colgroup width=\"80%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td>",
"        <strong>",
"         Biologic, anatomic, or natal gender (sex)",
"        </strong>",
"       </td>",
"       <td>",
"        Typically assigned according to external genitalia or chromosomes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Gender identity",
"        </strong>",
"       </td>",
"       <td>",
"        An individual's innate sense of feeling male, female, neither, or some combination of both",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Gender role behavior",
"        </strong>",
"       </td>",
"       <td>",
"        Society's expectations of attitudes, behaviors, and personality traits typically based on biologic sex; these cultural expectations are conveyed by \"masculinity\" and \"femininity\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Gender expression",
"        </strong>",
"       </td>",
"       <td>",
"        How gender is presented to the outside world (eg, feminine, masculine, androgynous); gender expression does not necessarily correlate with biologic gender (sex) or gender identity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Gender nonconformity",
"        </strong>",
"       </td>",
"       <td>",
"        Variation from the cultural norm in gender expression or gender role behavior (eg, in choices of toys, playmates, etc); other terms used similarly include \"gender variance\" or \"gender atypicality\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Gender discordance",
"        </strong>",
"       </td>",
"       <td>",
"        Discrepancy between anatomic sex and gender identity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         \"Transgender\"",
"        </strong>",
"       </td>",
"       <td>",
"        Umbrella term that is used to describe individuals with gender nonconformity; it includes individuals whose gender identity is different from their biologic sex and/or whose gender expression does not fall within stereotypical definitions of masculinity and femininity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Gender dysphoria",
"        </strong>",
"       </td>",
"       <td>",
"        Distress or discomfort that occurs if gender identity and anatomic sex are not completely congruent; not all gender discordant individuals experience gender dysphoria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Transsexuals",
"        </strong>",
"       </td>",
"       <td>",
"        Gender discordant people who make changes to their perceived gender and/or anatomic sex in order to conform with their gender identity through strategies such as dress, grooming, hormones, and/or surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Sexual orientation",
"        </strong>",
"       </td>",
"       <td>",
"        An individual's pattern of physical and emotional arousal (including fantasies, activities, and behaviors) and the gender(s) of persons to whom an individual is physically or sexually attracted (homosexual, heterosexual, bisexual); sexual orientation is an entirely different construct than gender identity, but is often confused with it",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Sexual behaviors",
"        </strong>",
"       </td>",
"       <td>",
"        Specific behaviors involving sexual activities that are useful for screening and risk assessment; many youth reject traditional labeling (homosexual, heterosexual, bisexual) but still have same sex partners",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * These are cultural and descriptive terms, not diagnostic terms, which are specific to medical and pathology based paradigms.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Perrin EC. Sexual Orientation in Child and Adolescent Health Care, Springer, New York 2002.",
"      </li>",
"      <li>",
"       Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, et al. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2009; 94:3132.",
"      </li>",
"      <li>",
"       American Academy of Child and Adolescent Psychiatry. Practice parameter on gay, lesbian or bisexual sexual orientation, gender-nonconformity, and gender discordance in children and adolescents.",
"       <a href=\"file://www.aacap.org/galleries/PracticeParameters/glbt_practice_parameter_june_2012.pdf\" target=\"_blank\">",
"        www.aacap.org/galleries/PracticeParameters/glbt_practice_parameter_june_2012.pdf",
"       </a>",
"       (Accessed on August 14, 2012).",
"      </li>",
"      <li>",
"       Frankowski BL, American Academy of Pediatrics Committee on Adolescence. Sexual orientation and adolescents. Pediatrics 2004; 113:1827.",
"      </li>",
"      <li>",
"       Edwards-Leeper L, Spack NP. Psychological evaluation and medical treatment of transgender youth in an interdisciplinary \"Gender Management Service\" (GeMS) in a major pediatric center. J Homosex 2012; 59:321.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_1_10269=[""].join("\n");
var outline_f10_1_10269=null;
var title_f10_1_10270="PEFR in esophageal infusion";
var content_f10_1_10270=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F78222&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F78222&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Peak expiratory flow rate during esophageal acid infusion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 434px; height: 257px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Peak expiratory flow rate data expressed as percent predicted during esophageal infusions of normal saline (NS) and acid.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Schan CA, Harding SM, Haile JM, et al, Chest 1994; 106:731.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_1_10270=[""].join("\n");
var outline_f10_1_10270=null;
var title_f10_1_10271="Contents: Diabetes";
var content_f10_1_10271=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?18/22/18798\">",
"       Patient Information",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Diabetes",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Diabetes",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Blood sugar monitoring",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/14/227\">",
"           Patient information: Hemoglobin A1C tests (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/43/39603\">",
"           Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/40/22144\">",
"           Patient information: The ABCs of diabetes (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Diabetes in children",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/52/37699\">",
"           Patient information: Carb counting and your child���������s diet (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/26/39331\">",
"           Patient information: Checking your child���������s blood sugar level (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/33/5651\">",
"           Patient information: Giving your child insulin (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/25/36243\">",
"           Patient information: Keeping your child���������s blood sugar under control (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/11/38066\">",
"           Patient information: Managing diabetes in school (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/48/18179\">",
"           Patient information: My child has diabetes: How will we manage? (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/43/692\">",
"           Patient information: Type 1 diabetes (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Diabetic kidney disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/4/24644\">",
"           Patient information: Diabetic kidney disease (diabetic nephropathy) (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Diabetic retinopathy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/35/11826\">",
"           Patient information: Age-related vision loss (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/34/11810\">",
"           Patient information: Diabetic retinopathy (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Diet",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/42/35490\">",
"           Patient information: Counting carbs if you do not use insulin (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/40/36483\">",
"           Patient information: Diabetes and diet (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/40/22144\">",
"           Patient information: The ABCs of diabetes (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/20/3397\">",
"           Patient information: Type 1 diabetes mellitus and diet (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/32/31239\">",
"           Patient information: Type 2 diabetes mellitus and diet (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Foot care",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/5/21587\">",
"           Patient information: Diabetic neuropathy (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/38/43618\">",
"           Patient information: Foot care in diabetes mellitus (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/47/20208\">",
"           Patient information: Nerve damage caused by diabetes (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/52/20292\">",
"           Patient information: Diabetes and infections (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Insulin",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/31/35317\">",
"           Patient information: Diabetes mellitus type 1: Insulin treatment (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/28/18886\">",
"           Patient information: Diabetes mellitus type 2: Insulin treatment (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/47/6899\">",
"           Patient information: Should I switch to an insulin pump? (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/58/28579\">",
"           Patient information: Using insulin (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Low blood sugar (hypoglycemia)",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/63/4083\">",
"           Patient information: Hypoglycemia (low blood sugar) in diabetes mellitus (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/12/14531\">",
"           Patient information: Low blood sugar in people with diabetes (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Metabolic syndrome",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/24/5507\">",
"           Patient information: Metabolic syndrome (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/56/42881\">",
"           Patient information: The metabolic syndrome (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pregnancy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/45/10966\">",
"           Patient information: Care during pregnancy for women with type 1 or 2 diabetes mellitus (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/62/31714\">",
"           Patient information: Care during pregnancy for women with type 1 or type 2 diabetes (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/46/12002\">",
"           Patient information: Gestational diabetes (diabetes that starts during pregnancy) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/13/32979\">",
"           Patient information: Gestational diabetes mellitus (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/47/15091\">",
"           Patient information: Preparing for pregnancy when you have diabetes (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Type 1 diabetes",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/52/20292\">",
"           Patient information: Diabetes and infections (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/31/35317\">",
"           Patient information: Diabetes mellitus type 1: Insulin treatment (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/26/36259\">",
"           Patient information: Diabetes mellitus type 1: Overview (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/2/36898\">",
"           Patient information: Diabetic ketoacidosis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/14/227\">",
"           Patient information: Hemoglobin A1C tests (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/63/4083\">",
"           Patient information: Hypoglycemia (low blood sugar) in diabetes mellitus (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/1/40980\">",
"           Patient information: Preventing complications in diabetes mellitus (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/43/39603\">",
"           Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/47/6899\">",
"           Patient information: Should I switch to an insulin pump? (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/40/22144\">",
"           Patient information: The ABCs of diabetes (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/43/692\">",
"           Patient information: Type 1 diabetes (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/58/28579\">",
"           Patient information: Using insulin (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Type 2 diabetes",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/52/20292\">",
"           Patient information: Diabetes and infections (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/60/6083\">",
"           Patient information: Diabetes mellitus type 2: Alcohol, exercise, and medical care (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/28/18886\">",
"           Patient information: Diabetes mellitus type 2: Insulin treatment (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/22/9572\">",
"           Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/37/36436\">",
"           Patient information: Diabetes mellitus type 2: Treatment (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/2/36898\">",
"           Patient information: Diabetic ketoacidosis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/14/227\">",
"           Patient information: Hemoglobin A1C tests (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/6/25699\">",
"           Patient information: Hyperosmolar nonketotic coma (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/63/4083\">",
"           Patient information: Hypoglycemia (low blood sugar) in diabetes mellitus (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/1/40980\">",
"           Patient information: Preventing complications in diabetes mellitus (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/25/15763\">",
"           Patient information: Preventing type 2 diabetes (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/43/39603\">",
"           Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/47/6899\">",
"           Patient information: Should I switch to an insulin pump? (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/40/22144\">",
"           Patient information: The ABCs of diabetes (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/49/16147\">",
"           Patient information: Treatment for type 2 diabetes (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/44/33475\">",
"           Patient information: Type 2 diabetes (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/58/28579\">",
"           Patient information: Using insulin (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-95BAA4DC3F-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f10_1_10271=[""].join("\n");
var outline_f10_1_10271=null;
